



QUALITY - EFFICIENCY - CUSTOMER SATISFACTION

ANNUAL REPORT

2025



LIST OF ABBREVIATIONS

JSC	Joint Stock Company
CSR	Corporate Social Responsibility
HOSE	Ho Chi Minh Stock Exchange
BOD	Board of Directors
CEO	Chief Executive Officer
GMS	General Meeting of Shareholders

TABLE OF CONTENT

1	GENERAL INFORMATION	
	OVERVIEW OF BIDIPHAR	03
	FORMATION AND DEVELOPMENT PROCESS	09
	OUTSTANDING AWARDS IN 2025	11
	BUSINESS LINE, PRODUCTION AND MARKET INFORMATION	12
	GOVERNANCE MODEL AND ORGANIZATION STRUCTURE	15
	RISKS	16
	BIDIPHAR'S DEVELOPMENT GOALS AND STRATEGY	17
	SUSTAINABLE DEVELOPMENT GOALS AND REPORT	21

2	OPERATIONS IN 2025	
	SITUATION OF PRODUCTION, BUSINESS OPERATIONS AND FINANCIAL IN 2025	30
	INVESTMENT PORTFOLIO, INVESTMENT ACTIVITIES, AND PROJECT IMPLEMENTATION	32
	STOCK INFORMATION, SHAREHOLDERS STRUCTURE, CHANGE IN THE OWNER'S EQUITY.	33

3	REPORTS AND ASSESSMENTS OF THE EXECUTIVE BOARD	
	ASSESSMENT OF OPERATING RESULTS AND FINANCIAL SITUATION IN 2025	35
	IMPROVEMENTS IN ORGANIZATIONAL STRUCTURE, POLICIES, AND MANAGEMENT.	38
	DEVELOPMENT PLANS IN FUTURE	39
	ASSESSMENT REPORT RELATED TO ENVIRONMENTAL AND SOCIAL RESPONSIBILITIES OF THE COMPANY	40

4	ASSESSMENTS OF THE BOARD OF DIRECTORS ON THE COMPANY'S OPERATION	
	ASSESSMENTS OF THE BOARD OF DIRECTORS ON THE COMPANY'S OPERATION	42
	ASSESSMENT OF BOARD OF DIRECTORS ON BOARD OF MANAGEMENT'S PERFORMANCE	45

5	CORPORATE GOVERNANCE	
	ACTIVITIES OF THE BOARD OF DIRECTORS	47
	REPORT OF THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS	49
	AUDIT COMMITTEE AND SUBCOMMITTEES OF THE BOARD OF DIRECTORS	51
	COMPENSATION & BONUS INFORMATION AND INTERNAL TRANSACTIONS	53

6	CONSOLIDATED FINANCIAL STATEMENT	
	CORPORATE INFORMATION	56
	STATEMENT OF THE EXECUTIVE BOARD	57
	INDEPENDENT AUDITOR'S REPORT	57
	CONSOLIDATED BALANCE SHEET	58
	CONSOLIDATED STATEMENT OF INCOME	59
	CONSOLIDATED STATEMENT OF CASH FLOWS	60
	NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT	61

MESSAGE FROM THE CHAIRMAN OF THE BOARD OF DIRECTORS

Over the past 45 years of establishment and development, Bidiphar has continuously innovated and fostered creativity to flexibly adapt to market fluctuations, while steadily making breakthroughs to fulfill its mission of

“ **CARE FOR HEALTH**
Share the Joy ”

Throughout its development journey, Bidiphar has always valued and deeply appreciated the companionship and support of our Shareholders, Partners, employees, as well as the trust of our Customers - key factors that have contributed to building a solid foundation for the Company's sustainable development.



Chairman of the Board of Directors
TA NAM BINH

Dear Esteemed Shareholders, Partners, Customers, and all Employees,

The year 2024 was another challenging year for the Company due to numerous fluctuations affecting the Vietnamese pharmaceutical industry, such as sharp increases in foreign exchange rates leading to higher input material costs, as well as changes in legal regulations (including bidding, prescription drug control, invoices, and taxation), which had a significant impact on pharmaceutical business operations.

2025 continued to be a challenging year for the Company, as numerous fluctuations in factors affecting the Vietnamese pharmaceutical industry—such as a sharp increase in foreign exchange rates leading to higher input material costs, along with changes in legal regulations (regarding bidding, prescription drug control, invoicing, and taxation)—had a significant impact on pharmaceutical business operations. In this context, the entire Company made relentless efforts to overcome these difficulties and achieved certain positive results, completing 97% of the revenue plan and 103% of the profit target. By the end of 2025, Bidiphar's net revenue and profit after tax reached 1865 billion VND and 292 billion VND, respectively. These encouraging business results were made possible by the relentless efforts of the entire Bidiphar team.

However, based on strategic orientations, the Board of Directors believes that in the coming period, the Company needs to continue strengthening its internal resources to enhance competitive advantages, while promoting growth to reinforce its position and align with the overall development prospects of the pharmaceutical industry.

Therefore, in the time ahead, the Company has identified the concentration of resources on key strategic objectives as a necessary requirement to enhance competitiveness and establish a solid foundation for sustainable growth. In line with this strategic orientation, the Company will focus on implementing the following key objectives:

- First, to continue investing in and completing the necessary conditions to meet GMP-EU standards for the oncology drug manufacturing plant and the small-volume sterile injectable manufacturing plant, thereby enhancing production capacity, product quality, and the ability to meet market demands.
- Second, to diversify the distributed product portfolio, prioritizing products with competitive advantages and high business efficiency, in alignment with the Company's development strategy in each phase.
- Third, to further diversify and develop distribution channels, expand market coverage, improve distribution efficiency, and minimize risks arising from dependence on a single distribution channel.

Throughout its 45 years of establishment and development, Bidiphar has consistently strived to overcome difficulties and challenges, gradually strengthening its capabilities and maintaining stable growth. With a sustainable development orientation, the Company has actively contributed to the care and protection of community health, while affirming its position in the pharmaceutical industry.

Once again, on behalf of Bidiphar, I would like to express my sincere appreciation and gratitude for your continued support, and I look forward to receiving your ongoing trust and long-term partnership in the years to come.

Sincerely,

Chairman of the Board of Directors
TA NAM BINH

GENERAL INFORMATION

OVERVIEW OF BIDIPHAR

FORMATION AND DEVELOPMENT PROCESS

OUTSTANDING AWARDS IN 2025

BUSINESS LINE, PRODUCTION AND MARKET INFORMATION

GOVERNANCE MODEL AND ORGANIZATION STRUCTURE

RISKS

BIDIPHAR'S DEVELOPMENT GOALS AND STRATEGY

SUSTAINABLE DEVELOPMENT GOALS AND REPORT



OVERVIEW OF BIDIPHAR

TRADING NAME	CÔNG TY CỔ PHẦN DƯỢC – TRANG THIẾT BỊ Y TẾ BÌNH ĐỊNH (BIDIPHAR)
ENGLISH NAME	BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JOINT STOCK COMPANY
ABBREVIATED NAME	BIDIPHAR
PHONE NUMBER	(84-256) 3846500

ADDRESS	No.498 Nguyen Thai Hoc Street, Quy Nhon Nam Ward, Gia Lai
FAX	+84 (256) 3846846
WEBSITE	https://bidiphar.com/
STOCK CODE	DBD – LISTED ON THE HO CHI MINH STOCK EXCHANGE (HOSE)
CHARTER CAPITAL	945,293,470,000 VND



ENTERPRISE VALUE

VISION

CONTINUE TO MAINTAIN IN THE TOP 5 LEADING PHARMACEUTICAL COMPANIES IN VIETNAM SPECIALIZING IN PROVIDING HIGH QUALITY PRODUCTS AND SERVICES, SERVING THE WORK OF COMMUNITY HEALTH CARE.

ACHIEVE TOP 3 VIETNAMESE PHARMACEUTICAL COMPANIES SPECIALIZING IN PROVIDING HIGH QUALITY HEALTHCARE PRODUCTS AND SERVICES BY 2030.

MISSION

CARE FOR HEALTH, SHARE THE JOY

PIONEER IN CREATING THE BEST PRODUCTS AND SERVICES TO TAKE CARE OF THE HEALTH OF VIETNAMESE PEOPLE.

CORE VALUES

MINDFULNESS

INTEGRITY

Transparent, honest, keeping commitments, and honoring promises.

SELF-REFLECTION

Always view oneself as the root of the problem. Be a role model, reflecting on yourself before judging others.

UNDERSTANDING

Respect, listen to understand, and find solutions to address the legitimate needs of colleagues, customers, and partners.

INTELLIGENCE

CLEAR OBJECTIVES

Always work with clear goals/KPIs. Plan, report, and make decisions based on data.

GOOD COLLABORATION

Respect differences – Connect with colleagues – Be relentless in pursuit of common goals.

EAGERNESS TO LEARN

Continuously learn management knowledge, expertise, and skills to apply in work and refine oneself and the team.

ADVANCEMENT

COURAGEOUS

Dare to think, dare to act, and take responsibility. Fear no difficulties and never give up.

CREATION

Always innovate and be creative at work.

PIONEERING

Lead in applying science, technology, and digital transformation to make a difference.

BOARD OF DIRECTORS

DIVERSITY - INDEPENDENCE - EFFICIENCY



MEMBERS OF THE BOARD OF DIRECTORS

Chairman of the Board of Directors

TÀ NAM BÌNH

Master of Business Administration
Date of Birth: 29/11/1975




Mr. Ta Nam Binh has held the position of Chairman of the Board of Directors of Bidiphar since 27/04/2024. Previously, he served as Vice Chairman of the Board of Directors of Bidiphar from 20/04/2019 to 27/04/2024.

- In addition, Mr. Binh has also held positions in other enterprises
- Vice Chairman of the Board of Directors of Mekong Hospital Co., Ltd
 - Chairman of the Board of Directors of Saigon Value Invest Corporation
 - Chairman of the Board of Members of Saigon Travel Co.,Ltd
 - Chairman of the Board of Directors of Tan Son JSC

Member of the Board of Directors

TRƯƠNG THANH LIÊM

Master of Business Administration
Date of Birth: 29/09/1983



Mr. Truong Thanh Liem has been a Member of the Board of Directors of Bidiphar since 21/04/2023. He has also held the position of Head of Internal Audit at Bidiphar from 01/01/2023 to 01/05/2025. Before joining Bidiphar, Mr. Liem worked at Nam A Commercial Joint Stock Bank and MHB Securities Joint Stock Company.

Other Positions: Vice Chairman of the Board of Directors of Value Plus Investment Corporation.

Member of the Board of Directors

NGUYỄN THỊ MINH GIANG

Bachelor of Information Technology,
Master of Finance
Date of Birth: 30/04/1981



Ms. Nguyen Thi Minh Giang has been a Member of the Board of Directors and Chairperson of the Audit Committee of Bidiphar since 27/04/2024; from 01/05/2025, she has also concurrently held the position of Head of the Internal Audit.

Other Positions:

- Founder and CEO of TIM Vietnam JSC.
- Independent member of the Board of Directors of Binh Minh Plastics JSC.



Member of the Board of Directors

PHẠM THỊ THANH HƯƠNG

Master of Pharmacy
Date of Birth: 10/07/1965



Ms. Pham Thi Thanh Huong has been working at Bidiphar since 2010. During this period, she has held the following positions:

- 2010 – 02/2014: Vice Chairperson of the Board of Directors and Deputy General Director of Binh Dinh Pharmaceutical and Medical Equipment Company, concurrently serving as Director of Bidiphar I JSC.
- 03/2014 – 04/2019: Vice Chairperson of the Board of Directors and Deputy General Director of Binh Dinh Pharmaceutical and Medical Equipment Company.
- 20/04/2019 – 17/04/2021: General Director of Binh Dinh Pharmaceutical and Medical Equipment JSC (Bidiphar).
- 17/04/2021 – Present: Member of the Board of Directors and General Director of Binh Dinh Pharmaceutical and Medical Equipment JSC (Bidiphar).

Other Positions:

- Chairperson of the Board of Members of Bidiphar Trading Co.,LTD.
- Chairperson of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

Previous Experience:

- Before working at Bidiphar, Mrs. Huong held the following roles:
- 2001 – 2007: Deputy Director of Binh Dinh Department of Health.
 - 2007 – 2009: Deputy Director of Binh Dinh Department of Home Affairs.

Member of the Board of Directors

NGUYỄN TIẾN HẢI

Diploma in Taxation
Date of Birth: 19/06/1972



Mr. Nguyen Tien Hai has been a member of the Board of Directors of Bidiphar since 27/04/2024. Previously, he served as:

- Member of the Board of Directors of Bidiphar from 20/04/2019 to 31/03/2023.
- Chairman of the Board of Directors of Bidiphar from 31/03/2023 to 27/04/2024.

Other Positions:

- Chairman of the Board of Directors and General Director of Kim Tin Group Corporation.
- Chairman of the Board of Directors and General Director of Kim Tin Investment And Development Corporation.

Member of the Board of Directors

PHAN TẤN THƯ

Bachelor of Economics
Date of Birth: 28/03/1983



Mr. Phan Tan Thu has been a Member of the Board of Directors of Bidiphar since 27/04/2024.

Other Positions:

- Member of the Board of Directors and General Director of Bao Minh Securities JSC.
- Director of Thien Phuc Technology JSC.

Member of the Board of Directors

NGUYỄN NGỌC DŨNG

Master of Pharmacy
Date of Birth: 12/08/1969



Mr. Nguyen Ngoc Dung has been a Member of the Board of Directors of Bidiphar since 21/04/2023.

He has also served as Deputy General Director of Bidiphar since 10/2019. Mr. Dung has been working at Bidiphar since August 1991, holding various positions, including Procurement Planning Staff, Sales Staff, Pharmacy Manager, Branch Manager, Deputy Head of Business Department and Head of Marketing Department at Bidiphar

Other Positions:

- Member of the Board of Members of Bidiphar Trading Co.,LTD.
- Member of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

EXECUTIVE BOARD

INTELLIGENCE - FORTITUDE - FLEXIBILITY



MEMBERS OF THE EXECUTIVE BOARD

General director

PHẠM THỊ THANH HƯƠNG

Master of Pharmacy
Date of Birth: 10/07/1965



Ms. Pham Thi Thanh Huong has been working at Bidiphar since 2010. During this period, she has held the following positions:

- 2010 – 02/2014: Vice Chairperson of the Board of Directors and Deputy General Director of Binh Dinh Pharmaceutical and Medical Equipment Company, concurrently serving as Director of Bidiphar I JSC.
- 03/2014 – 04/2019: Vice Chairperson of the Board of Directors and Deputy General Director of Binh Dinh Pharmaceutical and Medical Equipment Company.
- 20/04/2019 – 17/04/2021: General Director of Binh Dinh Pharmaceutical and Medical Equipment JSC (Bidiphar).
- 17/04/2021 – Present: Member of the Board of Directors and General Director of Binh Dinh Pharmaceutical and Medical Equipment JSC (Bidiphar).

Other Positions:

- Chairperson of the Board of Members of Bidiphar Trading Co.,LTD.
- Chairperson of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

Before working at Bidiphar, Mrs. Huong held the following roles:

- 2001 – 2007: Deputy Director of Binh Dinh Department of Health.
- 2007 – 2009: Deputy Director of Binh Dinh Department of Home Affairs.

Vice general director - Sales

NGUYỄN NGỌC DŨNG

Master of Pharmacy
Date of Birth: 12/08/1969



Mr. Nguyen Ngoc Dung has been a Member of the Board of Directors of Bidiphar since 21/04/2023.

He has also served as Deputy General Director of Bidiphar since 10/2019. Mr. Dung has been working at Bidiphar since August 1991, holding various positions, including Procurement Planning Staff, Sales Staff, Pharmacy Manager, Branch Manager, Deputy Head of Business Department and Head of Marketing Department at Bidiphar.

Other Positions:

- Member of the Board of Members of Bidiphar Trading Co.,LTD.
- Member of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

Vice General director - Production

BÀNH THỊ NGỌC QUỲNH

Master of Pharmacy
Date of Birth: 16/09/1969



Mrs. Banh Thi Ngoc Quynh has been working at Bidiphar since 1992. During this time, she has held various positions, including Staff Member in the Research and Drug Production Department, Deputy Director of Bidiphar I Company, Director of the R&D Center. She has served as Deputy General Director of the company since 12/2021.

Other Position: Member of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

Chief Accountant

ĐỖ HUY PHƯƠNG

Bachelor of Finance and Accounting
Date of Birth: 11/07/1982



Mr. Phuong has served as the Chief Accountant at Bidiphar since 01/09/2022. He has been working at Bidiphar since 2006 and has held various positions, including Accountant, Internal Control Team Leader, Chief Accountant of Bidiphar I Company and Deputy Head of the Accounting Department.

Other Positions:

- Member of the Board of Members of Bidiphar Trading Co.,LTD.
- Member of the Board of Members of Bidiphar Organic Medicine Co.,LTD.

FORMATION AND DEVELOPMENT PROCESS

1980 - 1989

READY FOR INNOVATION

26/09/1980

Bidiphar was established, originally known as Nghia Binh Pharmaceutical Enterprise II.

1992

Became the first Vietnamese pharmaceutical company to successfully produce injectable antibiotics.

05/05/1995

Merged with the Binh Dinh Medical Supplies and Pharmaceuticals Company, forming the Binh Dinh Pharmaceutical and Medical Equipment Company, abbreviated as Bidiphar.

1997

Pioneered the research and successful production of injectable solutions of antibiotics, vitamins, and protein.

1998

Established a pharmaceutical manufacturing plant meeting GMP-ASEAN standards and implemented an international quality management system (ISO).

1990 - 1999

PIONEERING STEPS

2000 - 2009

BRAND ESTABLISHMENT

2003

Became the first pharmaceutical company to apply freeze-drying technology in pharmaceutical production, marking a significant advancement in Vietnam's pharmaceutical industry at the time.

2006

Expanded production into antibiotics, vitamins, and hemodialysis solutions.

2009

Operated 11 production lines meeting GMP-WHO standards, GSP-compliant warehouses, and GLP-compliant laboratories. Built a distribution network with 8 branches and over 200 agencies in Binh Dinh and established 3 branches in Hanoi, Ho Chi Minh City, and Khanh Hoa.

2010 - 2018 STEADY INTEGRATION

2012

Became the first enterprise in Vietnam to successfully produce cancer treatment drugs.

2016

Established the first cancer drug manufacturing facility in Vietnam meeting GMP-WHO standards. Ranked in the Top 3 Most Reputable Pharmaceutical Companies in Vietnam.

2017

Partnered with Kyorin Group (Japan) and received technology transfer for in-vitro research (methods for studying microorganisms, cells, and biological molecules under laboratory conditions).

15/06/2018

Officially listed on the HOSE stock exchange under the stock code DBD.

2021

Successfully developed the technological process for manufacturing oral cancer treatment drugs.

2022

Partnered to develop a GMP-EU-standard manufacturing facility. Ranked in the Top 5 Most Reputable Pharmaceutical Companies in Vietnam.

2019 - 2025

TRANSFORMATION FOR THE FUTURE

2023


Inaugurated a GMP-EU-standard cancer drug manufacturing facility. Commenced construction of a small-volume sterile drug manufacturing plant meeting GMP-EU standards.

2024, 2025

Ranked in the Top 4 Most Reputable Pharmaceutical Companies in Vietnam.

Ranked among the Top 50 Listed Companies of 2025 by Forbes Vietnam.

OUTSTANDING AWARD
2025



INFORMATION BUSINESS LINE, PRODUCTION, AND MARKET

MAIN BUSINESS:
MANUFACTURE OF PHARMACEUTICALS,
MEDICINAL CHEMICAL AND BOTANICAL PRODUCTS

CANCER TREATMENT DRUGS

In 2012, Bidiphar marked a significant milestone when it received authorization from the Ministry of Health to circulate its first cancer treatment drug. This laid the foundation for Bidiphar to realize its dream of manufacturing cancer treatment drugs for Vietnamese patients, positioning Bidiphar as a leading pharmaceutical company in Vietnam to successfully produce this special type of medicine. By 2016, Bidiphar became the first enterprise in

Vietnam to have a cancer drug manufacturing plant meeting GMP-WHO standards. Today, Bidiphar's portfolio of cancer treatment drugs includes over 40 products used to treat various types of cancer. These products have gained trust and are widely used in most specialized hospitals and oncology departments, such as K Hospital, Ho Chi Minh City Oncology Hospital, Cho Ray Hospital, and Bach Mai Hospital.



HEMODIALYSIS SOLUTIONS

In 2011, Bidiphar became one of the first companies to produce hemodialysis solutions in the market. To date, these products have earned high trust from hospitals, doctors, and patients, ranking among the top 2 in Vietnam's market share. Bidiphar continues to invest in technology to develop new product lines and improve formulations, aiming to enhance the quality of life for dialysis patients.

Bidiphar recently signed a Memorandum of Understanding (MOU) with Crearene AG, a company based in Frauenfeld, Switzerland, to develop CREATINE-based treatment solutions for dialysis patients. This is a crucial step toward signing a technology transfer agreement, bringing new advancements to Vietnam's development of this product line.



ANTIBIOTICS

Bidiphar offers a diverse range of dietary supplements and herbal medicinal products, manufactured from high-quality raw materials. In 1992, Bidiphar successfully researched and produced injectable antibiotics. This achievement was not only a milestone for Bidiphar but also for the Vietnamese pharmaceutical industry, marking the first time a domestic pharmaceutical company could produce this special product form.

In 1997, Bidiphar successfully manufactured injectable solutions of antibiotics, vitamins, and amino acids. This breakthrough disrupted the monopoly of foreign pharmaceutical corporations,

contributing to market price stability and positioning Bidiphar as a leading pharmaceutical manufacturer in Vietnam, specializing in essential treatment products for healthcare facilities.

In 2003, Bidiphar reaffirmed its pioneering position by applying advanced formulation technologies to develop freeze-dried injectable drugs.

Currently, Bidiphar boasts a diverse portfolio of antibiotic products, including:

- 37 antibiotic compounds: Used in the production of the company's antibiotic products.
- 82 antibiotic products: Available in various dosage forms, such as injectable solutions, tablets, and others.



FUNCTIONAL FOODS – HERBAL MEDICINES

Bidiphar offers a wide range of functional foods and herbal medicines, produced from high-quality raw materials to meet the health care needs of consumers. These include product lines for vitamin and mineral supplementation, bone and joint support, liver function support, nervous system support, and care for diabetic patients, among others.

Bidiphar owns GACP-WHO certified

herbal gardens, cultivating 12 valuable medicinal plants such as *Gymnema*, *Solanum hainanense*, *Ampelopsis*, *Angelicasinensis*, *Codonopsis pilosula*, and *Morinda officinalis*. Owning such certified herbal cultivation areas ensures a clean and high-quality source of raw materials for production, enhancing the safety and effectiveness of Bidiphar's herbal and functional food products.



INFORMATION

BUSINESS LINE, PRODUCTION, AND MARKET

THE PRODUCTION AND DISTRIBUTION SYSTEM OF BIDIPHAR

PRODUCTION

PRODUCTION WORKSHOPS AT BIDIPHAR HEADQUARTERS

98 Nguyen Thai Hoc Street, Quy Nhon Nam Ward, Gia Lai Province, Vietnam.

PRODUCTION PLANTS AT BIDIPHAR NHON HOI BRANCH

Lot A3.01 - A3.02 - A3.03, Zone A, Nhon Hoi Economic Zone, Quy Nhon Dong Ward, Gia Lai Province, Vietnam.



DISTRIBUTION COVERING ALL 63 PROVINCES AND CITIES

16 BRANCHES NATIONWIDE AND 1 DISTRIBUTION COMPANY



BRANCH:

1. BIDIPHAR HA NOI BRANCH
2. BIDIPHAR PHU THO BRANCH
3. BIDIPHAR HAI PHONG BRANCH
4. BIDIPHAR THANH HOA BRANCH
5. BIDIPHAR NGHE AN BRANCH
6. BIDIPHAR QUANG TRI BRANCH
7. BIDIPHAR DA NANG BRANCH
8. BIDIPHAR QUANG NGAI BRANCH
9. BIDIPHAR TUY PHUOC BRANCH
10. BIDIPHAR DAKLAK BRANCH
11. BIDIPHAR KHANH HOA BRANCH
12. BIDIPHAR DONG NAI BRANCH
13. BIDIPHAR HO CHI MINH CITY
14. BIDIPHAR CAN THO BRANCH
15. BIDIPHAR TIEN GIANG BRANCH
16. BIDIPHAR KIEN GIANG BRANCH

EXPORT MARKETS

1. LAOS
2. YEMEN
3. MONGOLIA
4. CAMBODIA
5. MYANMAR

ETC CHANNEL: SUPPLYING OVER **2.000** HEALTHCARE FACILITIES


OTC CHANNEL: SUPPLYING NEARLY **16.000** PHARMACIES AND DRUG COUNTERS NATIONWIDE

DISTRIBUTION COMPANY: BIDIPHAR TRADING CO.,LTD

GOVERNANCE MODEL AND ORGANIZATION STRUCTURE

GOVERNANCE MODEL: The governance model follows the provisions outlined in Point b, Clause 1, Article 137 of the 2020 Enterprise Law, which includes:

- General Meeting of Shareholders;
- Board of Directors;
- Audit Committee under the Board of Directors;
- General Director.



RISKS

IDENTIFICATION OF KEY RISKS IN 2025

BIDIPHAR REGULARLY ASSESSES KEY RISKS IN A SYSTEMATIC MANNER, ENSURING THAT ALL RISKS ARE MANAGED PROMPTLY AND EFFECTIVELY.

	RISK IDENTIFICATION	RISK MONITORING AND MANAGEMENT
EXTERNAL RISKS	Bidiphar's business activities are susceptible to various external factors, encompassing elements such as economic conditions, political dynamics, regulatory frameworks, competitive landscapes, market fluctuations, environmental factors, societal trends, customer consumption patterns, and the repercussions of natural disasters or epidemics.	Establish a Company robust system for continuous monitoring of external factors and risk assessment system to promptly identify and evaluate changes in external variables that could impact Bidiphar's operations. Furthermore, Bidiphar shall develop a frequent business plan and consider diversifying its business operations to mitigate the adverse effects of unforeseen fluctuations. Additionally, ensuring cost optimization during operations is crucial to safeguarding business profitability amidst external uncertainties.
HUMAN RESOURCE RISKS	Bidiphar faces potential challenges related to human resources management and employment, shortages of highly skilled personnel, talent retention, and a sudden surge in demand for personnel.	Bidiphar should develop clear human resources policies, prioritize initiatives aimed at training and developing the skills of employees, create a safe and positive working environment conducive to attracting and retaining talent.

	RISK IDENTIFICATION	RISK MONITORING AND MANAGEMENT
INFORMATION TECHNOLOGY RISKS	<p>With the rapid evolution of information technology, Bidiphar may encounter challenges regarding judicious investment in technology and human capital, the capability to seamlessly integrate software/systems, and the efficient utilization of data resources/procedures for operational and commercial endeavors.</p> <p>Moreover, the company may confront cybersecurity and privacy vulnerabilities, potentially resulting in data breaches stemming from cyber assaults or security lapses.</p>	<p>Develop an Information Technology strategy for each phase, including:</p> <ul style="list-style-type: none"> The prioritization of investments should focus on technologies offering the most optimal returns, ensuring all expenditures are judicious and directly contribute to production and business objectives. Define an implementation roadmap for technology investments to ensure alignment with the objectives and resources of each period. <p>Establishing a robust security framework to safeguard customer information and corporate data against cyber threats is imperative.</p> <p>Regular assessment of IT systems and the formulation and enforcement of stringent information security protocols are essential.</p> <p>Implementation of measures such as data encryption, access control, and appropriate usage authorization is paramount.</p> <p>Continuous training of employees on cybersecurity and fostering awareness of technology risks are crucial in mitigating human-related risks</p>
REPUTATION RISK	<p>Concerns regarding product quality, conduct by employees or leadership, legal disputes, and adverse publicity on social media platforms.</p> <p>The issue of brand protection is also a concern for the Company, as it has recorded cases of Bidiphar brand counterfeiting.</p>	<p>Monitor customer feedback and communications to promptly assess and respond to incidents or negative information.</p> <p>Collaborate with authorities to combat online brand counterfeiting.</p>
OPERATIONAL RISKS	The production and trading of pharmaceutical products, which are directly related to human health, always carry quality risks during the operational process.	Establish a quality management system in accordance with ISO, GMP, GLP, GSP, and GDP standards in production and business operations.
ENVIRONMENTAL RISKS	Pharmaceutical production generates a significant amount of waste, including hazardous waste such as chemicals and cytotoxic drug by-products.	Apply waste treatment methods in compliance with GMP standards and relevant legal regulations to minimize environmental impact.

BIDIPHAR'S DEVELOPMENT GOALS AND STRATEGY


PHARMACEUTICAL MARKET OVERVIEW – IQVIA 2025

	2024 REVENUE (VND BILLION)	2024/2023 GROWTH (%)	2025 REVENUE (VND BILLION)	2025/2024 GROWTH (%)	PROPORTION (%)	NOTE
TOTAL	223,050	11%	234,794	5%	100%	
IMPORT	128,560	12%	139,630	9%	59%	Proportion of imported goods / domestically manufactured goods
LOCAL	94,490	8%	95,164	1%	41%	
LOCAL-HOSPITAL	31,284	9%	31,282	0%	33%	Hospital/Retail Channel Share (Domestically Manufactured-Products)
LOCAL-RETAIL	63,206	12%	63,882	5%	67%	

The data table shows that the pharmaceutical market reached VND 234,794 billion in 2025, representing a 5% increase compared to 2024. Although the market continues to grow, the growth rate has slowed from the 11% recorded in the previous year. Imported pharmaceuticals continue to account for the largest share of the market at 59% and recorded a growth rate of 9%, indicating that demand for foreign products remains strong. Meanwhile, domestically manufactured pharmaceuticals grew only slightly by 1%, reaching VND 95,164 billion, reflecting significant competitive pressure from imported products.

Within the structure of domestically manufactured pharmaceuticals, the retail channel accounts for the dominant share at 67% and recorded a growth rate of 5%, suggesting that it remains the main growth driver of the domestic market. In contrast, the hospital channel showed almost no growth (0%), with revenue remaining around VND 31,282 billion. This indicates that the expansion potential of domestically produced pharmaceuticals in the hospital channel remains limited and requires solutions to enhance competitiveness.

GROWTH AND MARKET SHARE BY DRUG CATEGORY AND REGION




ANALYSIS OF THE PHARMACEUTICAL INDUSTRY MARKET IN 2025

Prescription drugs (Ethical, excluding vaccines) continue to account for the largest share of the market structure across all regions, ranging from 56% to 66%. Meanwhile, OTC products also represent a significant proportion, particularly in areas outside Hanoi and Ho Chi Minh City (38%), reflecting the strong role of the retail channel in provincial markets.

In terms of growth, the Rx segment recorded increases in both Ho Chi Minh City (+6%) and Hanoi (+6%), contributing to the overall market expansion. In contrast, OTC products grew only in Ho Chi Minh City (+3%) but declined in Hanoi (-7%) and in other regions (-7%). The vaccine segment showed relatively strong growth in major urban areas, especially in Hanoi (+16%) and Ho Chi Minh City (+13%). Overall, market growth varies across regions and product groups, with prescription drugs in major cities serving as the primary growth driver.

GROWTH BY PHARMACOLOGICAL GROUP

Total Vietnam market -Top 15 leading ATC3 (Sales by value, Mn USD; FY 2025 growth, %)



The chart shows a clear divergence in growth among ATC3 therapeutic groups in the Vietnamese pharmaceutical market in 2025. Viral vaccines (J07E) recorded growth of approximately +15%, while bacterial vaccines (J07D) increased by around +10%, and both groups also represent large market segments. Meanwhile, monoclonal antibodies for oncology treatment (L01G – Mab antineoplastics) grew by about +15%, and lipid-modifying agents (C10A) increased by roughly +8%, reflecting rising demand for oncology therapies as well as cardiovascular and metabolic disease treatments.

In contrast, several commonly used drug groups show slower growth or even decline. For instance, non-narcotic analgesics (N02B) and other musculoskeletal products (M05X) recorded negative growth ranging from -3% to -10%. Overall, the market is shifting toward high-value and specialty therapeutic products, while conventional treatment categories face stronger competitive pressure and slower growth.

OPPORTUNITIES AND CHALLENGES



OPPORTUNITIES

External factors

- Public demand for healthcare services continues to increase.
- Universal healthcare activities receive greater attention and support from the State.
- Numerous legal regulations have been issued, supporting the development of the domestic pharmaceutical industry.

Internal factors of Bidiphar

- The Company's brand reputation continues to grow – ranked among the Top 4 most reputable pharmaceutical companies and recipient of many new awards.
- A diverse product portfolio; key product lines such as TUT solutions, renal dialysis solutions, and injectable antibiotics have built strong trust among hospitals.
- A nationwide distribution network, managed more effectively with supporting tools (SAP, DMS, Power BI, etc.).
- An increasingly stringent quality management system, ensuring compliance with regulations.
- Manufacturing facilities and equipment are regularly invested in and upgraded.
- A dedicated workforce with long-term commitment to the Company.



CHALLENGES

- Complex weather patterns and prolonged natural disasters in many localities have caused significant damage to facilities and inventories, adversely affecting production and business operations.
- Policies related to taxation, invoicing, and prescription drug control significantly impact sales activities in the pharmacy channel.
- The reorganization of administrative units after July 1, 2025 changes management areas and disrupts certain business activities, particularly in the hospital channel.
- Increased inspections and audits by regulatory authorities, while many procedures still require approvals with lengthy licensing timelines..
- The Company is currently implementing multiple projects (investment projects and management/digital transformation projects), leading to resource constraints; the project teams' experience with new projects remains limited.
- Intensifying market competition, with many new product registrations from competitors.
- The Company does not yet have a production line certified to EU-GMP standards.

COMPANY'S MEDIUM-TERM AND LONG-TERM DEVELOPMENT STRATEGY

ORIENTATION TOWARDS 2030

TOP 3

Most reputable Vietnam
pharmaceutical company

ACHIEVE **GMP-EU** for 3 production lines

- Oncology
- Small volume injection
- OSD Non-Betalactam

Revenue from
manufactured products reach

VND 3500 BILLION

EVALUATION OF IMPLEMENTATION ACTIVITIES

To achieve the established objectives, the Company has identified key priorities and focused its resources on their implementation. Specifically:

1

Investment in enhancing production capacity and quality standards

The Company has continued and will continue to invest in and complete the necessary conditions to meet EU-GMP standards for the oncology drug manufacturing plant and the small volume sterile drug manufacturing plant. Through these efforts, the Company has gradually enhanced its production capacity, product quality, and ability to meet market requirements.

2

Diversification and optimization of the product portfolio

The Company places strong emphasis on investment and allocates substantial resources to R&D activities, continuously researching new products and improving the quality of existing ones. These efforts aim to diversify the product portfolio, with priority given to products that offer competitive advantages and strong business efficiency, in line with the Company's development strategy in each phase.

3

Development and expansion of distribution channels

The Company consistently allocates significant resources to building and improving its distribution system with a strong focus on efficiency. In the present and going forward, the Company will continue to diversify and develop its distribution channels, expand market coverage, enhance distribution effectiveness, and mitigate risks arising from reliance on any single distribution channel.

GOALS PLAN FOR 2026

Achieve revenue exceeding

**VND 2,100
BILLION**

Profit before tax

**VND 375
BILLION**

ESG:

Continue to develop medicinal herb cultivation areas; utilize solar energy; protect the environment; and manage solid waste and wastewater, etc.

Improve the effectiveness of legal compliance updates: ensure 100% of legal documents relevant to the Company's operations are updated, communicated for implementation, and monitored through action plans.

By **31 December 2026**, complete:

- EU GMP assessment for the oncology drug manufacturing plant.

Comprehensive validation of the entire production and auxiliary equipment systems, including sanitation assessment and research/testing activities, for the SVI Plant.

Human resource management:

- Operate HR software and develop analytical management reports to identify issues and propose data-driven improvements based on the NSTL system.

- Increase labor productivity by over 10% through process improvement combined with digitalization.

- Achieve over 95% of tasks completed on time.



Communications and brand building:

- Maintain a position among the **TOP 4** most reputable pharmaceutical companies.

- Obtain National Brand certification for at least two product lines.

Financial management:

Finalize processes and financial management reporting (inventory, cash flow, cost of goods sold, selling expenses, branch operating expenses, etc.) to assess the efficiency of resource utilization across all core activities of the Company.

Continue to prioritize investment in R&D and new product development.

Continue to accelerate **DIGITAL TRANSFORMATION:** implement SAP S/4HANA, develop Power BI management reports, apply AI, develop Zalo mini apps, etc.

Finalize supply chain management processes, enhance forecasting effectiveness, ensure resource readiness, and deploy production to meet business requirements.

SUSTAINABLE DEVELOPMENT GOALS AND REPORT

Bidiphar's sustainable development goals revolves around the three pillars of Environment, Social, and Governance - ESG.

BIDIPHAR HAS MADE COMMITMENTS TO ACT RESPONSIBLY ACROSS
**ALL THREE ASPECTS:
ENVIRONMENT (E), SOCIAL (S), AND GOVERNANCE (G)**

ENVIRONMENT (E)


- Bidiphar is committed to the responsible use of natural resources.
- Bidiphar will develop a roadmap to reduce greenhouse gas emissions in alignment with the national plan by ensuring transparency in monitoring and reviewing emissions in its business and production activities.
- Bidiphar complies with legal regulations on waste management and works to minimize waste generation.
- Bidiphar enhances the efficient use of energy and resources by regularly monitoring energy and material usage, eliminating waste, and striving toward the appropriate adoption of renewable energy sources.

SOCIAL (S)

- Bidiphar fosters a diverse, equitable, and inclusive workplace by listening to and respecting differences, delegating authority with responsibility, encouraging opportunities, and providing deserved recognition.
- Bidiphar cares for its workforce across various aspects, such as mental health, social connection, and financial sustainability, through comprehensive employee welfare programs.
- Bidiphar invests in human capital development through strategic plans, HR policies, and initiatives that promote continuous learning for employees.
- Bidiphar spreads positive values through corporate social responsibility (CSR) activities.

GOVERNANCE (G)

- Bidiphar enhances the efficiency of the Board of Directors through an appropriate governance model and effective interaction with stakeholders.
- Bidiphar promotes a balance between the interests of the company, shareholders, and other related parties.
- Bidiphar is committed to adopting best practices in accounting by applying international accounting standards and maintaining a transparent and publicly accessible financial reporting system in accordance with the requirements and recommendations of regulatory authorities.
- Bidiphar ensures corporate transparency and legal compliance by fully and promptly disclosing corporate information and adhering to all legal regulations related to business activities.



SUSTAINABLE DEVELOPEMENT REPORT

ENVIRONMENT

GREENHOUSE GASES

GREENHOUSE GASES ARE ATMOSPHERIC GASES THAT CONTRIBUTE TO THE GREENHOUSE EFFECT.

Bidiphar is not listed among the industrial facilities required to perform greenhouse gas inventories under Decision No. 13/2024/QĐ-TTg dated August 13, 2024, by the Prime Minister.

However, recognizing the environmental impact of greenhouse gas emissions, Bidiphar is actively pursuing a plan to conduct greenhouse gas inventories while simultaneously developing an energy management system compliant with ISO 50001 standards to conserve energy and reduce emissions.

MANAGEMENT OF RAW MATERIALS

EFFICIENT AND EFFECTIVE USE OF RESOURCES.

Optimizing production to save raw materials is one of Bidiphar’s key objectives to achieve its business goals. The company has established and is implementing processes to monitor material usage and minimize waste during production in accordance with ISO and GMP standards.



ENERGY CONSUMPTION

ENERGY IS A VITAL FACTOR IN PRODUCTION. EFFICIENT ENERGY USE NOT ONLY REDUCES PRODUCTION COSTS BUT ALSO LOWERS POLLUTANT EMISSIONS.

Types of Energy Used at Bidiphar:

Electricity: Used in production for operating machinery, lighting, and air conditioning systems.

Gas: Utilized in specific production stages.

Gasoline/Diesel: Used for transportation, boiler operation, and power generation.

STATISTICAL YEAR	2022	2023	2024	2025
Electricity (kWh)	11,576,746	12,143,962	9,488,393	9,695,763
Diesel (liters)	142,748	153,700	164,100	179,800

ENERGY CONTROL

Bidiphar has implemented energy-saving measures over the years by encouraging employees to propose and execute annual energy-saving initiatives.

OPTIMIZATION OF PRODUCTION TIME

Bidiphar has established production management procedures to continuously streamline and schedule production activities, aiming to optimize production time and save energy.

WATER

WATER PLAYS A VITAL ROLE IN ALL PRODUCTION AREAS AT BIDIPHAR

In 2025, Bidiphar was not penalized for any violations of environmental laws and regulations. The company successfully balanced its production and business objectives with environmental protection goals by gradually adopting new technologies that ensure employee health and contribute to environmental preservation.

STATISTICAL YEAR	2022	2023	2024	2025
Water (m ³)	142.036	183.747	207.713	281.188

WASTEWATER & WASTE


Bidiphar focuses on investing in wastewater collection and treatment systems that comply with relevant standards at its Headquarters and Nhon Hoi Branch (two facilities conducting production activities). The company's wastewater and waste management activities follow two procedures: (i) regular waste management and (ii) hazardous waste management.

COMPLIANCE WITH ENVIRONMENTAL PROTECTION LAWS

In 2025, Bidiphar was not penalized for any violations of environmental laws and regulations. The company successfully balanced its production and business objectives with environmental protection goals by gradually adopting new technologies that ensure employee health and contribute to environmental preservation.

WASTEWATER TREATMENT SYSTEM AT BIDIPHAR NHON HOI I

(Capacity: 40m³/Per day)



PERSONNEL STRUCTURE

	2024	2025
Total (including BTC)	1380	1393
Executive Board	05	04
Middle manager	60	60
Employee	1315	1329
Workforce structure (excluding the Executive Board and Internal Audit)	1372	1387
Direct manufacturing personnel	344	347 (25,0%)
Direct sales personnel	327	303 (21,8%)
Production support personnel (including new projects)	347	378 (27,3%)
Business support personnel (including branches)	288	291 (21,0%)
General support functions (HR & Administration, IT, Accounting, etc.)	66	68 (4,9%)
New hires (including employees recruited in 2024 and commencing employment from January 2025)	175	137
Employee departures	99	124
Average monthly salary per employee	10 million VND	10,5 million VND



LABOR POLICIES TO ENSURE HEALTH, SAFETY AND WELFARE OF WORKERS

1. Attracting and retaining high-quality human resources.
2. Focusing on training and developing the team's capabilities.
3. Ensuring stable income for employees and fully complying with regulations on employee benefits.
4. Building a healthy, fair working environment that respects differences.
5. Complying with legal regulations and industry standards on occupational safety.
6. Complying with legal regulations on fire prevention and fighting.



TRAINING


At Bidiphar, generating advantages from human resources is always focused and invested in. In particular, leaders at all levels prioritize training activities and serve as role models. Learning opportunities are provided to all employees on an equal basis, with transparent training policies and procedures, clear rights and responsibilities between learners, direct managers, lecturers. This approach enables employees to be prepared to work in their current roles and to advance to higher positions for potential individuals.



OUTSTANDING TRAINING PROGRAMS OF 2025



AI and Business Applications



Occupational Safety and First Aid



Pharmacy Channel Sales Skills



Summer Practical Training for Medical and Pharmacy Students



Leadership Skills

RESPONSIBILITY FOR LOCAL COMMUNITY

Honoring Positive Values – Contributing to Social Welfare

In addition to its core manufacturing and business activities, Bidiphar annually allocates a budget of VND 2–4 billion to corporate social responsibility (CSR) initiatives, thereby reaffirming its commitment to accompanying communities and making meaningful contributions to social welfare. Notable programs that Bidiphar has implemented and continues to carry out include:



Bidiphar accompanied Provincial Party Secretary Hồ Quốc Dũng to visit and present Tet gifts to residents of An Dũng Commune on the occasion of the 2025 Lunar New Year.



Bidiphar accompanied Provincial Chairman Phạm Anh Tuấn to visit and present Tet gifts to residents of Dak Mang Commune on the occasion of the 2025 Lunar New Year.



Provision of 4,000 medical kits to communities in Northern Vietnam following Typhoon No. 11.



Bidiphar accompanied Provincial Chairman Phạm Anh Tuấn to visit and present Tet gifts at Kim Sơn Prison on the occasion of the 2025 Lunar New Year.



"20 Years of Accompanying Vietnamese Kidney Patients" Campaign: Visits and gift-giving for 1,251 chronic kidney patients receiving treatment at 17 medical facilities nationwide.



Provision of 3,000 medical kits to communities in Central Vietnam.



Provision of 1,000 medical kits to Gia Lai Province.



Provision of 2,000 medical kits to flood-affected communities in Central Vietnam.



Donation equivalent to one day's salary to the Vietnam Fatherland Front of Quy Nhơn Nam Ward to support disaster recovery efforts.



Donation of VND 500 million to the Vietnam Fatherland Front of Gia Lai Province.

OPERATIONS IN 2025



SITUATION OF PRODUCTION, BUSINESS OPERATIONS
AND FINANCIAL IN 2025

INVESTMENT PORTFOLIO, INVESTMENT ACTIVITIES,
AND PROJECT IMPLEMENTATION

STOCK INFORMATION, SHAREHOLDERS STRUCTURE,
CHANGE IN THE OWNER'S EQUITY

SITUATION OF PRODUCTION AND BUSINESS OPERATIONS IN 2025

FINANCIAL PERFORMANCE

NO.	ITEMS	UNIT	2021	2022	2023	2024	2025	% INCREASE/DECREASE (2025/2024)
1	Net revenue	Billion dong	1,558.5	1,554.8	1,651.8	1,727.5	1,865.4	8%
2	Cost of Goods Sold (COGS)	Billion dong	935.9	787.2	853.3	895.0	981.0	10%
3	Gross Profit	Billion dong	622.6	767.7	798.5	832.6	884.4	6%
4	Gross Profit Margin	%	40.0	49.4	48.3	48.2	47.4	(2%)
5	Net profit from business activities	Billion dong	230.9	298.7	322.0	329.1	349.1	6%
6	Other profits	Billion dong	1.6	-0.1	-1.9	-3.95	-3.05	22.8%
7	Profit before tax	Billion dong	232.4	298.6	320.1	325.1	346.1	6%
8	Profit after tax	Billion dong	189.1	243.6	269.1	275.2	291.9	6%

During the period 2021–2025, the Company's financial position maintained a stable growth trend. In 2025, net revenue reached VND 1,865.4 billion, representing an 8% increase compared to 2024. Meanwhile, cost of goods sold increased by 10%, resulting in a slight decrease in the gross profit margin to 47.4%. Nevertheless, operating efficiency was maintained as profit from operating activities reached VND 349.1 billion, up 6% year-on-year. In addition, other losses narrowed compared to 2024. As a result, profit before tax and profit after tax in 2025 reached VND 346.1 billion and VND 291.9 billion, respectively, both increasing by 6%, further confirming the Company's stable growth trajectory.

REVENUE STRUCTURE

NO.	ITEMS	2024 (Billions dong)	PROPORTION (%)	2025 (Billions dong)	PROPORTION (%)	% INCREASE/DECREASE (2025/2024)
1	Total Revenue	1,817.3	100	1,946.6	100	7%
1.1	Revenue from Pharmaceutical Production Sales	1752.3	96.42	1,879.2	96.54	7%
1.2	Revenue from Outsourced Pharmaceutical Sales	35.7	1.96	39.8	2.05	11%
1.3	Revenue from Medical Supplies Sales	8.4	0.46	4.8	0.69	(43%)
1.4	Revenue from Sales of Raw Materials, Packaging, and Tools	18.6	1.02	13.3	0.25	(28%)
1.5	Other revenue	2.3	0.13	9.5	0.49	413%
2	Other revenue	89.7	100	81.2	100	(9%)
2.1	Trade Discounts and Sales Rebates	86.1	96.00	74.7	91.99	(13%)
2.2	Sales Returns	3.6	4.00	6.5	8.01	(19%)
3	Net Revenue	1,727.5	-	1,865.4	-	8%

In 2025, the Company's total revenue reached VND 1,946.6 billion, representing a 7% increase compared to 2024. Revenue continued to be primarily driven by pharmaceutical products manufactured by the Company, accounting for approximately 96.5% of total revenue and recording a 7% growth. Revenue from traded pharmaceutical products also increased by 11%, while revenue from medical supplies and raw materials, packaging, and tools showed a declining trend compared to the previous year. In addition, revenue deductions decreased by 9%, contributing to net revenue reaching VND 1,865.4 billion in 2025, up 8% year-on-year. Overall, the revenue structure remained stable, with self-manufactured pharmaceutical products continuing to be the Company's key revenue driver.

KEY
FINANCIAL TARGETS

SOLVENCY	UNIT	2021	2022	2023	2024	2025	% INCREASE/ DECREASE
Current ratio	Time	3.30	3.08	3.02	3.21	2.52	(21%)
Quick ratio	Time	2.42	1.97	1.85	2.11	1.90	(10%)

In 2025, the Company's liquidity ratios declined compared to 2024, with the current ratio and quick ratio reaching 2.52 times and 1.90 times, respectively, representing decreases of 0.69 times (21%) and 0.21 times (10%) compared to the previous year. This was mainly attributable to increased capital requirements as the Company accelerated its investment activities during 2025. Nevertheless, these ratios remained at safe levels, indicating that the Company's short-term liquidity continued to be well maintained.

CAPITAL STRUCTURE	UNIT	2021	2022	2023	2024	2025	% INCREASE/ DECREASE
Debt/Total assets ratio	%	26.87	28.52	27.96	26.63	33.14	24%
Debt/Equity ratio	%	36.73	39.89	38.81	36.30	49.56	37%

In 2025, the Company's financial leverage ratios increased compared to 2024, with the debt-to-total assets ratio and debt-to-equity ratio reaching 33.14% and 49.56%, respectively (compared to 26.63% and 36.30% in 2024). This development reflects the Company's increased use of borrowed capital in the context of expanding investment activities. Nevertheless, these ratios remained at reasonable levels, indicating that the Company's capital structure continued to ensure financial safety.

OPERATIONAL CAPACITY	UNIT	2021	2022	2023	2024	2025	% INCREASE/ DECREASE
Inventory Turnover	Turns	3.68	2.23	1.82	1.80	2.25	5%
Total Asset Turnover	Turns	1.00	0.90	0.85	0.81	0.77	(5%)
Net Revenue/ Total Assets Ratio	Time	0.90	0.90	0.85	0.81	0.77	(5%)

In 2025, the Company's operating efficiency showed improvement in inventory management, with the inventory turnover ratio reaching 2.25 times, up 5% compared to 2024. In contrast, the total asset turnover and net revenue-to-total assets ratio slightly declined to 0.77 times, reflecting that asset utilization efficiency has not kept pace with the expansion in total assets as the Company accelerated its investment activities. Overall, the Company's operating efficiency remained relatively stable.

PROFITABILITY	UNIT	2021	2022	2023	2024	2025	% INCREASE/ DECREASE
Profit after tax/ Net revenue ratio	%	12.13	15.66	16.29	15.93	15.65	(2%)
Return on Equity (ROE)	%	17.75	19.52	19.30	16.57	16.81	1%
Return on Assets (ROA)	%	12.62	14.10	13.85	12.15	11.25	(7%)
Operating Profit Margin (OPM)	%	14.81	19.21	19.50	19.05	18.72	(2%)

In 2025, the Company's profitability indicators generally remained stable compared to 2024. The net profit margin and operating profit margin reached 15.65% and 18.72%, respectively, slightly decreasing from the previous year due to higher input costs and operating expenses. Meanwhile, ROE reached 16.81%, up 1% compared to 2024, indicating that the efficiency of utilizing shareholders' equity continued to be maintained. ROA declined to 11.25%, reflecting that the growth in total assets outpaced profit growth as the Company accelerated its investment activities.

ITEMS	UNIT	2021	2022	2023	2024	2025	% INCREASE/ DECREASE
Total Assets	Billion dong	1,559.5	1,895.7	1,988.9	2,264.2	2,596.2	15%
- Short-term Assets	Billion dong	948.2	1,247.8	1,260.7	1,476.3	1,480.0	0,25%
- Long-term Assets	Billion dong	611.3	647.9	728.2	787.9	1,116.2	42%
Liabilities	Billion dong	419.0	540.6	556.1	603.1	860.2	43%
- Short-term Debt	Billion dong	287.0	405.5	418.0	460.2	587.7	28%
- Long-term Debt	Billion dong	132.0	135.1	138.1	142.9	272.6	91%
Equity	Billion dong	1,140.5	1,355.1	1,432.8	1,661.1	1,736.0	5%

In 2025, the Company's total assets reached VND 2,596.2 billion, representing a 15% increase compared to 2024. Of this, non-current assets increased significantly by 42%, reflecting the Company's accelerated investments to expand its production and business operations, while current assets remained relatively stable. Total liabilities rose by 43%, mainly driven by a 91% increase in long-term liabilities and a 28% increase in short-term liabilities, indicating greater use of borrowed capital to finance investment activities. Meanwhile, equity continued to grow by 5%, contributing to maintaining a stable financial foundation and a sound capital structure.

LIST OF INVESTMENT PROJECTS, INVESTMENT SITUATION, AND IMPLEMENTATION OF INVESTMENT PROJECTS

No.	Investment Projects	Implementation Status
1	Investment in purchasing machinery and equipment for production and business activities.	Investments and procurement are carried out according to the resolutions approved by the Board of Directors and the Company's operational status for the year.
2	Repair and upgrade of production facilities.	Investments and procurement are carried out according to the resolutions approved by the Board of Directors and the Company's operational status for the year.
3	Construction of Branch Offices and other construction investment projects.	Investments and procurement are carried out according to the resolutions approved by the Board of Directors and the Company's operational status for the year.
4	Investment in purchasing equipment for the Oncology Drug Manufacturing Plant Project.	Procurement is carried out according to the resolutions approved by the General Meeting of Shareholders (GMS), with detailed content approved by the Board of Directors as per their authority.
5	Investment in constructing the Small-Volume Sterile Drug Manufacturing Plant Project and purchasing machinery and equipment.	Procurement is carried out according to the resolutions approved by the General Meeting of Shareholders, with detailed content approved by the Board of Directors as per their authority.



STOCK INFORMATION SHAREHOLDERS STRUCTURE, CHANGES IN CHARTER CAPITAL

STOCK INFORMATION BINH DINH PHARMACEUTICAL AND MEDICAL EQUIPMENT JSC

TYPE:	COMMON STOCK
STOCK CODE:	DBD
STOCK EXCHANGE	HOSE
CHARTER CAPITAL	945,293,470,000 VND
NUMBER OF OUTSTANDING SHARES:	94,489,262 SHARES
PAR VALUE:	10,000 VND PER SHARE
NUMBER OF TREASURY SHARE:	40,085 SHARES
NUMBER OF FREELY TRANSFERABLE SHARES:	93,587,233 SHARES
NUMBER OF RESTRICTED SHARES:	942,114 SHARES
FISCAL YEAR-END:	DECEMBER 31, 2025
INDEPENDENT AUDITOR:	ERNST & YOUNG VIETNAM CO., LTD

OWNERSHIP STRUCTURE BY TYPE OF SHAREHOLDER

NO.	SUBJECT	NUMBER OF SHARES	OWNERSHIP RATIO %	QUANTITY OF SHAREHOLDERS	SHAREHOLDER STRUCTURE	
					ORGANIZATION	INDIVIDUAL
1	State Shareholders	12,485,606	13.21%	01	01	0
2	Founding/FDI Shareholders	-	-	-	-	-
	- Domestic	-	-	-	-	-
	- Foreign	-	-	-	-	-
3	Major Shareholders	10,053,550	10.64%	01	01	0
	- Domestic	-	-	-	-	-
	- Foreign	10,053,550	10.64%	01	01	0
4	Trade Union	877,087	0.93%	02	02	0
	- Domestic	877,087	0.93%	02	02	0
	- Foreign	-	-	-	N/A	N/A
5	Treasury Shares	40,085	0.04%	01	01	N/A
6	Shareholders own preferred shares (if any)	-	-	-	-	-
7	Other shareholders	71,073,019	75.19%	2306	36	2270
	- Domestic	66,554,533	70.40%	2255	19	2236
	- Foreign	4,518,486	4.78%	51	17	34
TOTAL		94,529,347	100.00%	2311	41	2270
In which:						
- Domestic		79,957,311	84.58%	2259	23	2236
- Foreign		14,572,036	15.42%	52	18	34

EQUITY CHANGES STATISTICS

REGISTRATION	REASON	ISSUANCE DATE	CHARTER CAPITAL (dong)
FIRST REGISTRATION	First Registration	01/09/2010	146,866,000,000
ADJUSTMENT FOR THE FIRST TIME	Additional Registration	13/11/2013	155,564,818,097
ADJUSTMENT FOR THE 2ND TIME	Additional Registration	01/03/2014	268,627,000,000
ADJUSTMENT FOR THE 3RD TIME	Additional Registration	27/03/2014	268,627,000,000
ADJUSTMENT FOR THE 4TH TIME	Additional Registration	12/12/2014	268,627,000,000
ADJUSTMENT FOR THE 5TH TIME	Additional Registration	01/01/2015	419,182,790,000
ADJUSTMENT FOR THE 6TH TIME	Additional Registration	25/10/2016	523,790,000,000
ADJUSTMENT FOR THE 7TH TIME	Additional Registration	24/04/2019	523,790,000,000
ADJUSTMENT FOR THE 8TH TIME	Additional Registration	12/03/2020	523,790,000,000
ADJUSTMENT FOR THE 9TH TIME	Additional Registration	06/07/2021	576,124,440,000
ADJUSTMENT FOR THE 10TH TIME	Additional Registration	04/07/2022	748,835,590,000
ADJUSTMENT FOR THE 11TH TIME	Additional Registration	04/05/2023	748,835,590,000
ADJUSTMENT FOR THE 12TH TIME	Additional Registration	04/07/2024	935,938,470,000
ADJUSTMENT FOR THE 13TH TIME	Additional Registration	01/08/2025	935,938,470,000
ADJUSTMENT FOR THE 14TH TIME	Additional Registration	11/09/2025	945,293,470,000

REPORTS AND ASSESSMENTS OF THE EXECUTIVE BOARD



ASSESSMENT OF OPERATING RESULTS AND FINANCIAL
SITUATION IN 2025

IMPROVEMENTS IN ORGANIZATIONAL STRUCTURE,
POLICIES, AND MANAGEMENT

DEVELOPMENT PLANS IN FUTURE

ASSESSMENT REPORT RELATED TO ENVIRONMENTAL
AND SOCIAL RESPONSIBILITIES OF THE COMPANY

OVERVIEW OF HIGHLIGHTS IN 2025

1. Revenue reached VND 1,946 billion, representing 7% growth. Profit achieved 103% of the plan, up 6% year-on-year.
2. Essentially completed the construction, installation, and procurement for the SVI plant.
3. Financial management recorded significant improvements: effective management of receivables, inventory, and cash flow (including a 57-day reduction in the cash conversion cycle; bad debts down 55%, overdue receivables down 25%; financial income increased by VND 14 billion compared with 2024).
4. Human resource management made notable progress: company-wide implementation of the 3P salary system, total rewards framework, development of a competency dictionary, establishment of a KPI bank, detailed process data setup, staff rotation, and succession training.
5. Procurement activities of the Project Management Board and the Planning Department were effective thanks to competitive bidding and the search, evaluation, and selection of suppliers.
6. Digital transformation continued to be prioritized (deployment of HR-Payroll software, Zalo OA, Power BI for receivables; enhancements to DMS and SAP to meet departmental needs; implementation of information security tools and antivirus; rollout of e-contracts; a daily knowledge-check app for medical representatives; and digitalization of the equipment history tracking system).
7. The corporate brand continued to be reinforced through awards: maintaining Top 4 most reputable pharmaceutical companies, Top 50 listed companies, Top Vietnam Industry 4.0, Top 10 innovative enterprises, and Top 10 "Best Places to Work" in the pharmaceutical sector.
8. Successfully organized a series of activities celebrating the 45th anniversary of Bidiphar. Sponsorships and community engagement included:
 - Organizing community and social welfare programs totaling VND 1.6 billion, notably the "Run for Cancer Patients" program and the "Companion to 1,251 Kidney Patients" program.
 - Providing 10,000 medicine bags worth VND 1.8 billion, and VND 1.6 billion in support for communities affected by Typhoon No. 13 and floods in Thai Nguyen, Hue, Da Nang, Dak Lak, and Gia Lai.
9. Implemented over 370 initiatives across the Company, delivering benefits worth tens of billions of VND.
10. Achieved excellent results in the proficiency testing program of the National Institute of Drug Quality Control for both testing laboratories at Nguyen Thai Hoc and Nhon Hoi.

ASSESSMENT OF OPERATING RESULTS AND FINANCIAL SITUATION IN 2025

TARGETS	UNIT	2024	2025	%CHANGE
Total Assets	Billion dong	2,264.2	2,596.2	14.66%
Net revenue	Billion dong	1,727.5	1,865.4	7.98%
Net profit from business activities	Billion dong	329.1	349.1	6.08%
Other profits	Billion dong	-4.0	-3.05	22.8%
Profit before tax	Billion dong	325.1	346.1	6.46%
Profit after tax	Billion dong	275.2	291.9	6.07%

In 2025, the Company's total assets reached VND 2,596.2 billion, an increase of 14.66% compared to 2024, indicating an expansion in its scale of operations. Net revenue amounted to VND 1,865.4 billion, up 7.98%, reflecting stable growth in business activities. Profit from operating activities reached VND 349.1 billion, increasing by 6.08%, demonstrating that operational efficiency was maintained at a positive level. Profit before tax and profit after tax were VND 346.1 billion and VND 291.9 billion, respectively, representing increases of 6.46% and 6.07% compared to the previous year. In addition, losses from other activities decreased compared to 2024, contributing to an improvement in the Company's overall profit performance.

NET REVENUE

HOSPITAL CHANNEL REVENUE

In 2025, revenue from the hospital channel reached VND 1,173.9 billion, fulfilling 100% of the plan and increasing by 10% compared to 2024 (VND 1,062 billion). This channel continued to be the largest contributor to the Company's total revenue.

PHARMACY CHANNEL REVENUE

Revenue from the pharmacy channel in 2025 reached VND 642.6 billion, achieving only 89% of the plan and increasing slightly by 2% compared to 2024 (VND 630.7 billion). The modest growth reflects challenges in the pharmaceutical retail market, including changes in customers' purchasing behavior and stricter regulations on prescription drugs. In addition, competition from large pharmacy chains also put pressure on sales performance.

FINANCIAL SITUATION

ASSET SITUATION

ITEMS	2024 (BILLION DONG)	PROPORTION (%)	2025 (BILLION DONG)	PROPORTION (%)	%2025/ 2024
Total Assets	2,264.2	100	2,596.2	100	114.66
Short-term Assets	1,476.3	65.20	1,480.0	57.01	100.25
Long-term Assets	787.9	34.80	1,116.2	42.99	141.67

In 2025, the Company's total assets reached VND 2,596.2 billion, an increase of 14.66% compared to 2024, indicating that the Company continued to expand its asset base. Current assets amounted to VND 1,480.0 billion, remaining almost unchanged from the previous year (up 0.25%), resulting in a decrease in their proportion from 65.20% to 57.01% of the total asset structure. Meanwhile, non-current assets increased significantly by 41.67% to VND 1,116.2 billion, raising their proportion from 34.80% to 42.99%. The notable growth in non-current assets indicates that the Company has been accelerating investments in long-term assets to support its production and business operations. Overall, the asset structure has shifted toward a higher proportion of non-current assets, reflecting the Company's strategy to invest in and expand its operations.

LIABILITIES SITUATION

ITEMS	2024 (BILLION VND)	PROPORTION (%)	2025 (BILLION VND)	PROPORTION (%)	%2025/ 2024
Total Liabilities	603.1	100	860.2	100	142.63
Short-term Debt	460.2	76.30	587.7	68.31	127.71
Long-term Debt	142.9	23.7	272.6	31.69	190.76

In 2025, the Company's total liabilities reached VND 860.2 billion, an increase of 42.63% compared to 2024, indicating a higher level of borrowed capital and financial obligations. Short-term liabilities amounted to VND 587.7 billion, up 27.71%; however, their proportion in total liabilities decreased from 76.30% to 68.31%. Meanwhile, long-term liabilities increased significantly by 90.76% to VND 272.6 billion, raising their proportion from 23.7% to 31.69%. The notable increase in long-term liabilities indicates that the Company has been strengthening its mobilization of long-term capital to support investment and business expansion. Overall, the liability structure has shifted toward a higher proportion of long-term liabilities, contributing to a more balanced capital maturity structure.

INTRODUCTION TO THE BUSINESS ACTIVITIES OF SUBSIDIARIES

BIDIPHAR TRADING CO.,LTD

Charter Capital: 30 BILLION DONG

Ownership by Bidiphar: 100%

Main Business Activities: Wholesale of other household goods (Details: Wholesale of pharmaceutical drugs, herbal medicines, traditional medicines, medicinal herbs, cosmetics; Wholesale of medical instruments and supplies).

Bidiphar Trading Co.,LTD serves as a strategic piece to consolidate Bidiphar's distribution system. BTC distributes both externally sourced products and those manufactured by Bidiphar.

ITEMS	2024 (Unit: million dong)	2025 (Unit: million dong)	%2025/2024
Total Assets	44,040.1	51,346.7	116.59%
Net revenue	168,177.6	179,639.7	106.82%
Cost of Goods Sold (COGS)	135,620.4	145,191.4	107.06%
Revenue from Financial Activities	97.9	229.7	234.63%
Selling, Administrative, and Financial Expenses	(21,040.6)	(23,413.2)	(111.28%)
Net profit from business activities	11,614.5	11,264.8	96.99%
Other profits	(243.3)	(521.1)	(214.18%)
Profit before tax	11,371.2	10,743.7	94.48%
Profit after tax	9,014.9	8,466.8	93.92%

BIDIPHAR ORGANIC MEDICINE CO., LTD

Charter Capital: 5 BILLION DONG

Ownership by Bidiphar: 100%

Main Business Activities: Manufacturing of pharmaceuticals, chemicals, and medicinal materials (Details: Production of pharmaceuticals, raw materials for medicines, pharmaceutical preparations, chemical drugs, and medicinal herbs).

Bidiphar Organic Medicine Co.,LTD (Biomed) plays a key role in refining Bidiphar's production system. Currently, Biomed focuses on cultivating organic medicinal herbs and supplying them to Bidiphar for the production of herbal-based products, notably:

- Gymnema - Hebamic: Supports blood sugar reduction for diabetes patients.
- Solanum procumbens and Eurycoma longifolia - Bidiphar Liver Supplement: Aids in liver detoxification.
- Ampelopsis cantoniensis – Nhat Vi Linh: Helps alleviate symptoms of gastritis and duodenitis.

ITEMS	2024 (Unit: million dong)	2025 (Unit: million dong)	%2025/2024
Total Assets	6,238.1	6,855.7	109.90%
Net revenue	2,420.0	1,733.1	71.62%
Cost of Goods Sold (COGS)	1,259.1	1,923.2	152.74%
Revenue from Financial Activities	136.9	135.7	99.12%
Selling, Administrative, and Financial Expenses	198.7	292.7	147.31%
Net profit from business activities	1,099.1	347.1	31.58%
Other profits	5.0	398.4	7,968.00%
Profit before tax	1,104.2	51.2	4.64%
Profit after tax	1,104.2	47.6	4.31%

IMPROVEMENTS IN ORGANIZATIONAL STRUCTURE POLICIES, AND MANAGEMENT

1

Adjusting the organizational structure in line with changes in administrative boundaries

In 2025, the Company implemented adjustments to its organizational structure to align with the Government's policy on the reorganization of administrative boundaries. At the same time, the Company reviewed and reorganized the operating territories of its sales branches and restructured certain departments and units, based on the principles of appropriateness, improved management efficiency, and optimized resource utilization.

2

Standardizing workload, staffing levels, and the human resource management system

The Company recorded initial positive progress in reviewing and improving matters related to workload allocation, staffing norms, the development of a KPI bank, and the standardization of job positions. To ensure these changes were implemented in a consistent and appropriate manner, the Company developed and standardized all core processes at both the Company level and across individual departments and units, thereby establishing a solid foundation for systematic and transparent management.

3

Enhancing employee welfare policies toward transparency and consistency

Policies on compensation, benefits, and employee welfare continued to be reviewed, refined, and standardized in a clearer and more transparent manner, helping to safeguard employees' legitimate interests and strengthen engagement across the Company's workforce.

4

Strengthening coordination and executive effectiveness across the organization

Direction, management, and coordination between the Executive Management and departments/units, as well as among departments and units themselves, have become increasingly seamless, cohesive, and effective, thereby improving overall operational efficiency and supporting the achievement of the Company's business and production objectives.

DEVELOPMENT PLANS IN FUTURE

The Executive Board focuses all resources on implementing:


- The objectives for 2026.
- The company's medium- and long-term development strategy.

(These two contents are detailed on Chapter 1 – General Information)

During the operations, the Executive Board submits periodic and ad-hoc reports to seek guidance from the Board of Directors regarding the company's business activities.

The Board of Directors has mechanisms to monitor and supervise

the Executive Board implementation of the Resolutions/Decisions of the Board of Directors. The Board of Directors also maintain regular interaction with the Executive Board outside of scheduled meetings to stay informed and provide timely guidance.



2026 TARGET PLAN

TO BE SUBMITTED TO THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS

STT	TARGETS	UNIT	ACTUAL PERFORMANCE IN 2025	PLAN IN 2026	GROWTH RATE (%)
1	Charter capital	Billion dong	945	945	0%
2	Total revenue	Billion dong	1,947	2,090	7%
3	Pre-tax profit	Billion dong	344	375	9%

NEW INVESTMENT PLAN

The Executive Board continues to assess and carry out related tasks to finalize the investment plan for the OSD-Non Betalactam Factory Project, which was approved at the 2024 Annual General Meeting of Shareholders.



ASSESSMENT REPORT RELATED TO
**ENVIRONMENTAL AND SOCIAL
RESPONSIBILITIES OF THE COMPANY**

Annually, the Executive Board proactively carries out activities related to the company's environmental and social responsibilities in accordance with the budget and directives approved by the Board of Directors. In 2025, the Executive Board successfully completed outstanding environmental and social initiatives,

with detailed activities outlined on Chapter 1 of this report. In 2026, the Executive Board will continue to uphold and enhance the company's environmental and social responsibility efforts as per the established plans and strategies, contributing to the sustainable development of the company.



ASSESSMENTS OF THE BOARD OF DIRECTORS ON THE COMPANY'S OPERATION

ASSESSMENTS OF THE BOARD OF DIRECTORS
ON THE COMPANY'S OPERATION

ASSESSMENT OF THE BOARD OF DIRECTORS
ON THE EXECUTIVE BOARD'S PERFORMANCE

ASSESSMENTS OF THE BOARD OF DIRECTORS ON THE COMPANY'S OPERATION

IN 2025, THE BIDIPHAR TEAM MAINTAINED RELATIVELY STABLE OPERATIONS, OVERCOMING NUMEROUS INTERNAL AND EXTERNAL CHALLENGES.

97%

OF THE PLANNED
REVENUE FOR 2025

103%

OF THE PLANNED
PROFIT FOR 2025

THE COMPANY HAS EFFECTIVELY FULFILLED ITS OBLIGATIONS TO THE STATE BUDGET, WHILE DELIVERING SUBSTANTIAL BENEFITS TO SHAREHOLDERS, EMPLOYEES, AND SOCIETY

DIVIDEND PAYMENT

Bidiphar successfully completed the dividend payment for 2024 in 2025.

OPERATIONAL CONTEXT IN 2025

In 2025, the production and business activities of Bidiphar took place amid an interplay of opportunities and challenges. Public demand for healthcare continued to increase, while universal healthcare activities received greater attention and investment from the Government. At the same time, numerous new legal regulations were promulgated in a direction supportive of the domestic pharmaceutical industry, creating favorable conditions for enterprises to enhance their competitiveness. Conversely, complex weather patterns and prolonged natural disasters in many localities caused significant damage to infrastructure and goods, adversely affecting production and business operations. Policies related to taxation, invoicing, and prescription drug control continued to have a considerable impact on sales activities through the pharmacy channel. The reorganization

of administrative units after 1 July 2025 altered management boundaries, resulting in certain disruptions to business operations, particularly in the hospital channel. In addition, inspections and audits by regulatory authorities increased, while many administrative procedures continued to require lengthy approval timelines. At the same time, the Company implemented multiple investment, management, and digital transformation projects, placing substantial pressure on resources and execution capabilities. Amid increasingly intense market competition, with a growing number of new product registrations from competitors, the absence of a GMP-EU-certified production line remained a challenge to market expansion and the enhancement of the Company's competitive position.

EVALUATION OF GENERAL MEETING OF SHAREHOLDERS ORGANIZATION

The information regarding meetings and resolutions of the General Meeting of Shareholders is as follows:

No.	Resolutions No.	Date	Content
1	55/BB-ĐHĐCĐ2025	26/04/2025	Minutes of the 2025 Annual General Meeting of Shareholders
2	56/NQ-ĐHĐCĐ2025	26/04/2025	Resolution of the 2025 Annual General Meeting of Shareholders

PERFORMANCE REVIEW FOR 2025

SALES AND MARKETING ACTIVITIES

In 2025, Bidiphar deployed dedicated sales teams for the Chain-Distributor (NPP) customer segment, expanded the distributor network, and successfully introduced products into nationwide chains, resulting in revenue growth of 30%. Sales management effectiveness was enhanced through structured planning, weekly ASM reporting on OneDrive, and the organization of regular coordination meetings. Tender performance continued to improve, with the number of successful bids among 500 major tender packages increasing by 38%, of which key product groups achieved a success rate of 92%. The Company implemented a range of key sales programs, including “gold promotion”

campaigns, direct gold purchases delivered from the Company to individual branches, as well as product portfolio orientation and promotional programs with free-of-charge goods, contributing to optimized selling expenses and increased revenue from the pharmacy channel. In parallel, close coordination with the IT department in deploying standardized forms, cross-checking promotional programs on the system prior to effectiveness, standardizing the creation of delivery orders on SAP for all branch and relevant unit orders, together with the successful market launch of SPM Eyetamin New, contributed to improved operational efficiency and overall business performance.

REMUNERATION POLICIES, HUMAN RESOURCES, AND CAPABILITY DEVELOPMENT

In 2025, the Company continued to refine and implement the Total Remuneration Policy, comprising salary, seven types of bonuses, five types of allowances, and nineteen types of benefits, while adjusting upward the salary base for social insurance contributions in accordance with the Branch and Workshop Salary Regulations. Support and reward policies were fully implemented, including home-visit support of over VND 150 million, fuel allowances for the sales force amounting to VND 900 million, internal hospitality expenses exceeding VND 1.3 billion, rewards for outstanding teams and individuals totaling VND 950 million, and ad-hoc rewards of VND 80 million for individuals making effective contributions to flood prevention and firefighting activities. The Company also issued and standardized various HR management procedures such as leave registration, timekeeping and

payroll calculation, and the innovation reward process, under which rewards were granted for 370 initiatives with a total value of VND 1.152 billion. At the same time, a training matrix was developed for all job positions with 625 SOPs applied company-wide, alongside the completion of a competency dictionary, KPI bank, and the implementation of staff rotation to develop succession talent. Based on the standardization of functions, responsibilities, and core processes of each department, the Company gradually established detailed process data to support labor norm setting, staffing levels, job descriptions, KPIs, and risk assessment, while drafting the competency assessment procedure and implementing training programs for successor managers from deputy manager level upward, laying the groundwork for competency assessment from 2026.

FINANCIAL MANAGEMENT ACTIVITIES

In 2025, the Company's financial management recorded significant positive progress. Inventory management improved markedly, with inventory over 12 months and inventory aged 9-12 months reduced by 50% compared with 2024, while products with remaining shelf life of less than six months continued to decline on a monthly basis. Receivables were effectively controlled, with bad debts decreasing by 55% and overdue receivables by 25% compared with 2024, thereby contributing to improved cash flow and an increase in financial income of VND 14 billion year-on-year.

As a result of these comprehensive improvements in working capital management, the Company's cash conversion cycle was shortened by 72 days compared with 2024. In addition, the Company strengthened monthly and quarterly financial statement analysis to provide timely advice to the Executive Management and reports to the Board of Directors, while issuing new Payment Procedures and Cost Control Procedures and continuing to develop procedures on tax management, inventory provision, and budgeting and budget control.

INTERNAL COMMUNICATIONS AND SOCIAL ACTIVITIES

In 2025, the Company successfully organized a series of activities celebrating the 45th anniversary of Bidiphar, contributing to the reinforcement of its corporate image and brand values. In parallel, sponsorship and community engagement activities continued to be actively promoted, with total contributions of VND 1.6 billion through various social welfare programs, notably the “Run for Cancer Patients” program and the “Companion to 1,251 Kid-

ney Patients” program. In response to damage caused by Typhoon No. 13 and subsequent flooding, the Company promptly provided financial support totaling VND 1.6 billion to assist affected communities. In addition, the Company donated 10,000 medicine bags with a total value of VND 1.8 billion to residents in Thai Nguyen, Hue, Da Nang, Dak Lak, and Gia Lai provinces, clearly demonstrating its social responsibility and commitment to community development.

MANUFACTURING ACTIVITIES

In 2025, the Company's product costs were significantly improved through the diversification of raw material supply sources, optimization of purchasing batch sizes, utilization of import market data, and strengthened negotiations with suppliers, resulting in total raw material procurement cost savings exceeding VND 3.5 billion. In addition, the Company proactively supplemented

alternative raw material sources, conducted early control of DMF dossiers, and extended retest periods for raw materials, thereby minimizing the risk of production disruption and enhancing preparedness in meeting production plans. Alongside cost management efforts, the Company effectively implemented initiatives to maximize manufacturing capacity utilization and promptly meet market demand.

QUALITY MANAGEMENT SYSTEM

In 2025, Bidiphar completed GSP assessment and GACP recertification, and successfully conducted surveillance audits in accordance with ISO/IEC 17025:2017, ISO 9001:2015, and ISO 13485 standards. The Company implemented, assessed, and resolved 99% of changes to the quality system and products within the prescribed timelines, ensuring full compliance with change evaluation, approval, and control procedures and minimizing risks during implementation. At the same time, the Company proactively reviewed, supplemented, and applied appropriate raw material

sources in production to ensure product quality and stability. The update and implementation of GMP-WHO guidelines and 22 new regulations and circulars were completed, enhancing compliance and ensuring readiness for inspections and audits by regulatory authorities. In addition, the Company proactively identified 70 quality risks related to both systems and products, effectively controlled testing costs with savings of VND 2.5 billion, and ensured timely delivery of testing results to meet production requirements.

DIGITALIZATION ACTIVITIES

In 2025, the Company continued to accelerate digital transformation in management and operations. The human resources and payroll software project reached approximately 90% completion and is expected to be officially operational in the second quarter of 2026. The Company deployed a Zalo Official Account and applied ZNS messaging to notify pharmacy-channel customers of delivery and payment status from June 2025, thereby enhancing transparency and customer service quality, while also developing Power BI reports for revenue and receivables management.

In addition, the DMS and SAP systems were further enhanced to meet departmental requirements, including the development of additional transaction codes (T-codes) to more effectively leverage the SAP ERP system for data statistics, control, and management. At the same time, the Company implemented information security solutions, applied electronic sales contracts for 100% of customers, developed a daily knowledge-check application for medical representatives, and digitalized the system for tracking equipment operation history, maintenance, and servicing.

ASSESSMENT OF THE BOARD OF DIRECTORS ON THE EXECUTIVE BOARD'S PERFORMANCE

IN ACCORDANCE WITH THE COMPANY'S CHARTER AND INTERNAL REGULATIONS ON CORPORATE GOVERNANCE, THE BOARD OF DIRECTORS HAS REVIEWED AND SUPERVISED THE ACTIVITIES OF THE GENERAL DIRECTOR AND THE EXECUTIVE BOARD IN THE AREAS OF PRODUCT OPERATIONS AND TRADING, AND THE IMPLEMENTATION OF RESOLUTIONS FROM THE GENERAL MEETING OF SHAREHOLDERS AND THE BOARD OF DIRECTORS IN 2025.

• The members of the Board of Directors frequently attended Executive Board meetings and maintained regular communication with the Executive Board. Through this, the Board of Directors gained a clear understanding of the company's operations, decisions, and management activities. The effective coordination between the Board of Directors and the Executive Board facilitated the timely and accurate decisions and policies necessary to overcome market and business challenges, achieving optimal results for the company's operations.

• Additionally, the Committees/Subcommittees of the Board of Directors organized meetings, provided advice, conducted critical evaluations, and engaged in professional discussions with the General Director and members of the Executive Board on relevant matters. These activities aimed to enhance the operational efficiency of the Executive Board while assessing the company's performance across various areas.

• The Board of Directors closely monitored the General Director and the Executive Board in corporate governance, business, and financial risk management, ensuring compliance with legal and state regulations.

• Overall, the Board of Directors acknowledges the relentless efforts of the General Director, the Executive Board, and all employees of the company in successfully overcoming market challenges in 2025 achieving commendable results.

COMPANY'S MEDIUM-TERM AND LONG-TERM DEVELOPMENT STRATEGY

ORIENTATION TOWARDS 2030

TOP 3

Most reputable Vietnam pharmaceutical company

Achieve **GMP-EU** for 3 production lines:

- Oncology
- Small volume Injection
- OSD Non-Betalactam

Revenue from manufactured goods exceeded

3500

BILLION VND

CORPORATE GOVERNANCE

ACTIVITIES OF THE BOARD OF DIRECTORS

REPORT OF THE INDEPENDENT MEMBERS
OF THE BOARD OF DIRECTORS

AUDIT COMMITTEE AND SUBCOMMITTEES OF
THE BOARD OF DIRECTORS

COMPENSATION & BONUS INFORMATION AND
INTERNAL TRANSACTIONS

ACTIVITIES OF THE BOARD OF DIRECTORS

The Board of Directors operated effectively, adhering to high standards of governance and ensuring transparent, efficient information disclosure in all business activities:

The Board of Directors held nearly 10 meetings in 2025, following the procedures and requirements stipulated by law, the company's charter, and internal corporate governance regulations.

The Board of Directors also conducted written voting through online platforms.

Through meetings and voting sessions, the Board of Directors issued minutes/resolutions/decisions to fulfill its rights and responsibilities, as well as implement resolutions of the GMS.

Regarding the protection of shareholder rights, equitable treatment among shareholders, and enhancing the effective participation and balanced interests of stakeholders: The Board of Directors implemented strict controls over internal and related-party transactions by issuing the Regulation on Controlling Transactions with Affiliated Parties on September 14, 2025. This regulation was

carefully designed and executed to ensure compliance with legal requirements and principles of transparency. This approach guarantees transparency in transactions, prevents conflicts of interest, and fosters a reliable and stable operating environment, promoting sustainable and harmonious development for all stakeholders.

The Board of Directors consistently emphasizes fostering a corporate culture focused on sustainable development and incorporates risk management and internal control systems as key objectives of the company.

Regarding the activities of the Board of Directors' Committees/Subcommittees: Overall, the Audit Committee and other subcommittees of the Board of Directors were assessed as performing well in 2025. They provided advice, developed recommendations, and monitored the implementation of the company's business and operational plans. Proposals aimed at improving operational and business efficiency were acknowledged and scheduled for execution in 2025.

BOARD OF DIRECTORS MEETING

NO.	BOARD OF DIRECTOR'S MEMBER	NUMBER OF MEETINGS ATTENDED BY BOARD OF DIRECTORS	ATTENDANCE RATE	REASONS FOR ABSENCE
1	Tạ Nam Bình	5/5	100%	N/A
2	Nguyễn Thị Minh Giang	5/5	100%	N/A
3	Phạm Thị Thanh Hương	5/5	100%	N/A
4	Nguyễn Ngọc Dũng	5/5	100%	N/A
5	Nguyễn Tiến Hải	4/5	80%	Personal reasons
6	Phan Tấn Thư	5/5	100%	N/A
7	Trương Thanh Liêm	5/5	100%	N/A

NO.	RESOLUTION/ DECISION NO.	DATE	CONTENT
1	02/NQ-HĐQT	08/01/2025	Resolution on the Approval of the 2024 Internal Audit Activity Report and the 2025 Activity Plan
2	03/QĐ-HĐQT	08/01/2025	Decision on the Additional Appointment of Personnel to the Internal Audit Department
3	05/NQ-HĐQT	21/01/2025	Resolution on the 2025 Activity Plan of the IR Subcommittee
4	06/BC-DBD	21/01/2025	2024 Report on Corporate Governance
5	08/NQ-HĐQT	06/02/2025	Resolution on the Approval of the Strategic Subcommittee's Performance Report for the Second Half of 2024 and the 2025 Activity Plan
6	11/NQ-HĐQT	12/02/2025	Resolution on approving the contents to be submitted to the General Meeting of Shareholders concerning the 2025 business and production plan
7	14/QĐ-HĐQT	19/02/2025	Decision on the Approval of the Contractor Selection Results for Package XL4: HVAC, BMS, and EMS Systems under the Small-Volume Parenteral Drug Manufacturing Plant Project
8	16/NQ-HĐQT	22/02/2025	Quarter I/2025 Regular Board of Directors' Resolution
9	18/QĐ-HĐQT	26/02/2025	Decision on the Approval of the Contractor Selection Results for the Water System Package for the Workshop and QC Area under the Small-Volume Parenteral Drug Manufacturing Plant Project
10	19/NQ-HĐQT	27/02/2025	Resolution on the Record Date for Exercising Rights
11	21/QĐ-HĐQT	14/03/2025	Decision on the Approval of the Contractor Selection Results for Package XL8 – Epoxy Coating under the Small-Volume Parenteral Drug Manufacturing Plant Project
12	23/QĐ-HĐQT	22/03/2025	Decision on the Approval of the Contractor Selection Results for Package XL6 – Medium and Low Voltage System under the Small-Volume Parenteral Drug Manufacturing Plant Project
13	30/QĐ-HĐQT	02/04/2025	Decision on the Approval of the Contractor Selection Results for Package XL9 – Design, Construction, and Appraisal of the Fire Protection System under the Small-Volume Parenteral Drug Manufacturing Plant Project
14	31/QĐ-HĐQT	02/04/2025	Decision on the Approval of the Investment Policy for the Solar Power System Project at the Nhon Hoi Oncology Drug Manufacturing Plant
15	32/QĐ-HĐQT	02/04/2025	Decision on the Approval of the Contractor Selection Results for Package XL11 – Supply, Installation, Evaluation, and Handover of the Industrial Steam Generation and Distribution System under the Small-Volume Parenteral Drug Manufacturing Plant Project
16	33/QĐ-HĐQT	02/04/2025	Decision on the Approval of the Contractor Selection Results for Package XL3 – Construction of Auxiliary Works and Technical Infrastructure under the Small-Volume Parenteral Drug Manufacturing Plant Project
17	34/QĐ-HĐQT	02/04/2025	Decision on the Approval of the Contractor Selection Results for Package XL7 – Design, Supply, Installation, Evaluation, and Handover of Panels, Passboxes, and Access Control System under the Small-Volume Parenteral Drug Manufacturing Plant Project
18	47/NQ-HĐQT	03/04/2025	Resolution on the Approval of the 2025 Annual General Meeting Documents
19	49/QĐ-HĐQT	11/04/2025	Decision on the Approval of the 2025 Investment and Procurement Plan
20	51/QĐ-HĐQT	12/04/2025	Decision on the Approval of the Contractor Selection Results for Package XL7.1 – Procurement of Cleanroom Equipment: Laminar and Downflow Booths under the Small-Volume Parenteral Drug Manufacturing Plant Project

NO.	RESOLUTION/DECISION NO.	DATE	CONTENT
21	54/NQ-HĐQT	25/04/2025	Resolution for the Meeting on April 26, 2025
22	57/QĐ-HĐQT	28/04/2025	Decision on the Dismissal from the Positions of Head of the Internal Audit Department
23	58/QĐ-HĐQT	28/04/2025	Decision on the Assignment to Concurrently Hold the Position of Head of the Internal Audit Department
24	59c/NQ-HĐQT	05/05/2025	Resolution on Borrowing, Providing Guarantees, Opening Letters of Credit, and Using Assets as Collateral at BIDV
25	59d/NQ-HĐQT	05/05/2025	Resolution on Borrowing from Vietcombank
26	60/QĐ-HĐQT	06/05/2025	Decision on the Distribution of the 2024 Board of Directors' Remuneration Fund
27	65/QĐ-HĐQT	12/05/2025	Decision on the Approval of the Contractor Selection Results for the Laboratory Tables, Fume Hoods, Furniture, and Laboratory Equipment Package under the Small-Volume Parenteral Drug Manufacturing Plant Project
28	66/QĐ-HĐQT	12/05/2025	Decision on the Approval of the Salary Range for the Position of Company Secretary cum Corporate Governance Officer and the Adjustment of the Incumbent's Salary
29	68/QĐ-HĐQT	13/05/2025	Decision on the Dismissal from the Position of Deputy Head of the Internal Audit Department
30	75/QĐ-HĐQT	27/05/2025	Decision on the Approval of the Contractor Selection Results for Package XL5 – Design, Equipment Supply, Installation, Evaluation, and Handover of the Power and Lighting System under the Small-Volume Parenteral Drug Manufacturing Plant Project
31	79/QĐ-HĐQT	30/05/2025	Decision on the Appointment of Internal Audit Department Personnel
32	80/QĐ-HĐQT	30/05/2025	Decision on the Approval of the Salary Ranges for Positions in the Internal Audit Department and the Arrangement and Adjustment of Salaries for Internal Audit Department Personnel
33	81/QĐ-HĐQT	30/05/2025	Decision on the Approval of the Contractor Selection Results for the Human Resources and Payroll Management Software System Package
34	81b/QĐ-HĐQT	30/05/2025	Decision on the Approval of the Bidiphar Office Building Project
35	83/NQ-HĐQT	04/06/2025	Quarter II/2025 Regular Board of Directors' Resolution
36	84/QĐ-HĐQT	04/06/2025	Decision on the Approval of the 2025 Supplemental Investment and Procurement Plan
37	85/QĐ-HĐQT	04/06/2025	Decision on the Approval of the Implementation of the Employee Stock Option Plan (ESOP)
38	86/QĐ-HĐQT	04/06/2025	Decision on the Issuance of the ESOP Regulation
39	87/QĐ-HĐQT	04/06/2025	Decision on the Approval of the List of Employees Eligible for ESOP Subscription Rights
40	89/QĐ-HĐQT	10/06/2025	Decision on the Adjustment of Investor Information and the Implementation Schedule of the Investment Project for the Small-Volume Parenteral Drug Manufacturing Plant at Lot A3.03, Nhon Hoi Industrial Park (Zone A), Nhon Hoi Economic Zone, Nhon Hoi Commune, Quy Nhon City, Binh Dinh Province, Vietnam
41	91/NQ-HĐQT	10/06/2025	Resolution on Borrowing from the Binh Dinh Province Development Investment Fund
42	92/NQ-HĐQT	13/06/2025	Resolution on the Approval of the 2024 Cash Dividend Payment to Existing Shareholders
43	94/QĐ-HĐQT	16/06/2025	Decision on the Approval of the Contractor Selection Results for the Phase 1 and Phase 2 Testing Equipment Package under the Small-Volume Parenteral Drug Manufacturing Plant Project (Second Approval)
44	96/QĐ-HĐQT	27/06/2025	Decision on the Allocation of Odd Shares Arising from Rounding Down in the Distribution of Shares to Employees under the 2025 ESOP Program

NO.	RESOLUTION/DECISION NO.	DATE	CONTENT
45	98/NQ-HĐQT	03/07/2025	Resolution on the selection of the auditing firm for the 2025 Financial Statements
46	99/BC-DBD	21/07/2025	Corporate Governance Report (6-month period)
47	101/QĐ-HĐQT	21/07/2025	Decision on the proposal regarding the organizational format of the 2026 Annual General Meeting of Shareholders (AGM)
48	102/QĐ-HĐQT	31/07/2025	Decision regarding the registration procedures and payment for share purchases under the 2025 Employee Stock Ownership Program (ESOP) of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar)
49	104/QĐ-HĐQT	04/08/2025	Decision approving the contractor selection results for Package XL15 – Passenger Elevator of the Small-Volume Sterile Pharmaceutical Manufacturing Plant Project
50	106/BB-HĐQT	04/08/2025	Decision on approving the results of contractor selection for the Testing Equipment Package – Phase 1 and Phase 2 under the Small-Volume Sterile Pharmaceutical Manufacturing Plant Project (Third Approval)
51	108/QĐ-HĐQT	19/08/2025	Decision approving the selection results of the service provider for the organization of the Annual General Meeting of Shareholders
52	110/QĐ-HĐQT	20/08/2025	Decision approving the contractor selection results for Package XL13 – Design, manufacture, supply, installation, and transfer of the gas generation and distribution system (compressed air, nitrogen, liquefied gas) of the Small-Volume Sterile Pharmaceutical Manufacturing Plant Project.
53	112/NQ-HĐQT	22/08/2025	Quarter III/2025 Regular Board of Directors' Resolution
54	114/QĐ-HĐQT	27/08/2025	Decision on approving the results of share allocation under the 2025 Employee Stock Ownership Program (ESOP) of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar)
55	116/QĐ-HĐQT	09/09/2025	Decision on approving the results of contractor selection for Package XL14 – Construction and installation of the low-voltage (ELV) system and the synchronized time clock system under the Small-Volume Sterile Pharmaceutical Manufacturing Plant Project
56	118/QĐ-HĐQT	23/09/2025	Decision on approving the additional investment and procurement plan for 2025
57	121/QĐ-HĐQT	13/10/2025	Decision approving the orientation/policy on the selection of successor personnel for the position of Deputy General Director
58	123/QĐ-HĐQT	28/11/2025	Decision regarding the appointment of personnel to the Internal Audit
59	124/QĐ-HĐQT	28/11/2025	Decision on the reappointment of personnel to the Internal Audit
60	126/NQ-HĐQT	03/12/2025	Quarter IV/2025 Regular Board of Directors' Resolution
61	128/NQ-HĐQT	08/12/2025	Resolution approving the project's total investment capital, loan borrowing, and the use of assets as security for the implementation of the Small-Volume Sterile Pharmaceutical Manufacturing Plant Investment Project at the Joint Stock Commercial Bank for Investment and Development of Vietnam (BIDV) – Binh Dinh Branch
62	130/NQ-HĐQT	19/12/2025	Decision on approving the investment in a 10-liter dialysis solution can filling line at the Dialysis Solution Production Workshop – 498 Nguyen Thai Hoc
63	133/QĐ-HĐQT	25/12/2025	Decision on approving the results of contractor selection for the package on renovation of the HVAC system for the microbiological testing room, replacement of water-based FCUs with gas-based FCUs at Beta-lactam Powder Injection Workshop 2, and installation of an AHU for the Isolator at Nhon Hoi Branch
64	134/QĐ-HĐQT	25/12/2025	Decision on approving the termination of operations of Dong Thap Branch and the conversion of Dong Thap Branch's operating model into a business location under Can Tho Branch.
65	135/QĐ-HĐQT	25/12/2025	Decision on approving the policy for upgrading and expanding the SAP ERP software system
66	137/QĐ-HĐQT	27/12/2025	Decision on approving the supplementary investment and procurement plan for 2026

REPORT OF THE INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS

LIST OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS

The Board of Directors of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) consists of 02 independent members, accounting for 28% of the total Board of Directors members, in compliance with the Enterprise Law No. 59/2020/QH14, issued on July 17, 2020, and Clause 4, Article 276 of Decree 155/2020/ND-CP, which guides the implementation of the Securities Law.

The independent members of the Board of Directors are:

- Mr. Tạ Nam Bình: Chairman of the Board of Director.
- Ms. Nguyễn Thị Minh Giang: Member of the Board of Directors – Chairperson of the Audit Committee.

REPORT OF THE INDEPENDENT BOARD MEMBER – TẠ NAM BÌNH

1. Overall results of supervision of the Company's operations

• The Company's production and business activities over the past 1–2 years have shown signs of slowing after a period of strong growth, mainly due to the fact that the implementation and achievement of certain strategic objectives for the 2022–2026 period have not met expectations.

• In the next phase, the Board of Directors and the Executive Management ("EM") need to focus more decisively on implementing key task groups for the 2026–2030 period in order to enhance competitiveness and establish a foundation for sustainable growth. Based on the strategic orientation, the Company will focus on implementing the following key objectives:

+ Continue to invest in and complete the necessary conditions to meet GMP-EU standards for the cancer drug manufacturing plant and the small-volume parenteral manufacturing plant, thereby enhancing production capacity, product quality, and the ability to meet market requirements.

+ Diversify the distributed product portfolio, prioritizing products with competitive advantages and strong business efficiency, in line with the Company's development orientation in each period.

+ Further diversify and develop distribution channels, expand market coverage, improve distribution efficiency, and mitigate risks arising from dependence on any single distribution channel.

2. Assessment results of the internal control system and risk management

• Human resource risk has been identified as one of the Company's key risks. In practice, this risk has had and continues to have a significant impact on the Company's operations, as the Company is facing numerous difficulties and challenges, including those arising from external factors. The Board of Directors has directed the Executive Management to strengthen

training efforts, develop high-quality human resources, and formulate and implement a succession planning program to ensure stability and sustainable development of the Company.

• The Company's internal control activities still require further enhancement, particularly within the Business Division and the Support Division. The Board of Directors has

oriented the establishment of dedicated functions for Legal Affairs, Internal Control, and Risk Management to strengthen inspection and supervision during operations. In addition, during the period before such dedicated functions are established, the Executive Management should regularly conduct inspections and assessments of the Company's internal control activities in order to review and mitigate risks arising in production, operations, and business activities.

• The Board of Directors continues to carry out post-supervision activities through the Audit Committee and the Internal Audit Department. In 2025, the Board of Directors conducted surveys and collected feedback from the Executive Management and relevant departments on perspectives regarding risk assessment and risk management, as a basis for improving the effectiveness of the Internal Audit Department's activities in 2026.

3. Results of supervision over the Board of Directors and the Executive Board

• Members of the Board of Directors should devote more time to studying, reviewing, and promptly contributing opinions on strategic matters that have an impact on the Company's production and business performance in both the short and long term. Currently, the level of participation and input on certain matters is not yet truly consistent among members.

• The Executive Management should continue to strengthen its advisory role and proactively and promptly provide complete information as requested by the Board of Directors, in order to ensure a sufficient basis for the Board's review and decision-making. At present, in some cases, the information provided remains incomplete or not sufficiently timely as required.

REPORT OF THE INDEPENDENT BOARD MEMBER IN THE AUDIT COMMITTEE – NGUYỄN THỊ MINH GIANG

1. Remuneration, operating expenses, and other benefits of the Audit Committee and each Audit Committee member

• The remuneration, operating expenses, and other benefits of the Audit Committee and each Audit Committee member were in full compliance with the provisions of the Law on Enterprises and the Company's Charter.

Detailed information is presented in the audited 2025 Financial Statements and the 2025 Report on the Activities of the Board of Directors.

2. Meetings of the Audit Committee and its conclusions and recommendations

Meetings of the Audit Committee:

• In its role of directly overseeing the Internal Audit Department, the Audit Committee held quarterly meetings (04 meetings in 2025) to provide direction and supervise the activities of the Internal Audit Department.

• The conclusions and recommendations of the Internal Audit Department were reviewed, assessed, and agreed upon by the Audit Committee before being submitted to the Board of Directors and the Executive Management for implementation.

Conclusions and recommendations of the Audit Committee:

• The Executive Management should regularly update and improve internal regulations and departmental operating procedures to enhance productivity and the effectiveness of internal control activities.

• The Executive Management should establish a mechanism to monitor the implementation of internal audit recommendations to ensure that agreed matters are effectively executed in practice.

• The Executive Management should continue to improve the quality of reports and be more proactive and transparent in information disclosure to support the decision-making process of the Board of Directors.

3. Results of supervision over the financial statements, operating performance, and financial position

- The 2025 financial statements were prepared in accordance with accounting standards and applicable laws; were duly issued under proper authority and complied with disclosure requirements for listed companies; and fairly and faithfully reflected the Company's financial position.
- The audit firm selected for 2025 (Ernst & Young Vietnam Limited Liability Company) ensured reliability and integrity, complied

with audit timelines and professional standards, and maintained independence and objectivity in issuing audit opinions.

- The Company's 2025 financial statements were audited by Ernst & Young Vietnam Limited Liability Company, thereby providing independent assurance on the accuracy and reliability of the disclosed financial information.

4. Transactions between Bidiphar's insiders, related parties of insiders, and subsidiaries or entities controlled by Bidiphar

- Bidiphar complied with relevant regulations on approval authority, monitoring, and disclosure of transactions between its insiders, related parties of insiders, and Bidiphar,

its subsidiaries, and entities under its control. These transactions were duly disclosed in accordance with applicable laws.

5. Results of assessment of the internal control system and risk management

- The internal control and risk management system has been well established in the Manufacturing Division (in line with industry standards); however, there remain areas for improvement in the Business Division and the Support Division.

procedures related to operations, thereby enhancing the effectiveness of the internal control system.

- The Executive Management has gradually reviewed departmental operational processes and amended, supplemented, and newly issued documents, including regulations and

6. Results of supervision over the Board of Directors and the Executive Management

Activities of the Board of Directors

- In 2025, the activities of the Board of Directors complied with legal requirements and the Company's internal regulations. Resolutions and decisions of the Board of Directors were duly issued and complied with information disclosure obligations.
- Members of the Board of Directors fully complied with regulations on participation in Board meetings, and conducted discussions and voting in an independent and objective manner to best safeguard the interests of the Company.
- The Board of Directors proposed timely and effective solutions to support the Executive Management in operating the Company, and effectively carried out supervision and control to ensure compliance with laws and regulations.
- The Board of Directors supervised the Executive Management and management officers in implementing resolutions of the General Meeting of Shareholders; executing resolutions and decisions of the Board of Directors; and man-

aging production and business operations in compliance with laws and internal regulations, without undermining the Executive Management's autonomy in day-to-day operations.

Activities of the Executive Board:

- The Executive Management fully and promptly implemented resolutions and decisions of the General Meeting of Shareholders and the Board of Directors, and effectively executed the Company's production and business plans.
- The Executive Management demonstrated strong proactiveness in managing the Company's production and business operations.
- Members of the Board of Directors holding executive positions regularly attended both regular and extraordinary meetings of the Executive Management. Important decisions of the Executive Management were analyzed, reviewed, and consulted with the Board of Directors to ensure the Company's best interests.

7. Results of assessment of coordination between the Audit Committee, the Board of Directors, the General Director, and shareholders

- The Audit Committee proactively coordinated with the Board of Directors and the General Director in performing its duties, in

compliance with the provisions of the Audit Committee's Operating Regulations as promulgated.

AUDIT COMMITTEE AND SUBCOMMITTEES OF THE BOARD OF DIRECTORS

AUDIT COMMITTEE

INFORMATION ABOUT AUDIT COMMITTEE MEMBERS

NO.	Member of Audit Committee	Position	Start date as a member of Audit Committee	Date of no longer being a member of Audit Committee	Professional Qualifications
1	Nguyễn Thị Minh Giang	Chairperson	27/04/2024	N/A	Bachelor of Information Technology, Master of Finance
2	Phan Tấn Thư	Member	27/04/2024	N/A	Bachelor of Economics

REPORT OF THE AUDIT COMMITTEE

General Activities of the Audit Committee:

- Collaborated with the Board of Directors and Executive Board to oversee the company's adherence to legal requirements, charter provisions, and operational regulations.
- Assessed and recommended the appointment of an independent auditor for the 2025 financial statements, and supervised the Internal Audit in overseeing the auditor's examination of the financial statements.
- Directed the Internal Audit to assess and evaluate the company's internal control and risk management framework.
- Supervised the Company Secretary in reviewing and evaluating related transactions, and finalized regulations for monitoring and reviewing transactions involving Internal Persons and related parties.
- Oversaw and evaluated the Internal Audit's activities for the year 2025.

AUDIT COMMITTEE MEETING

NO.	Member of Audit Committee	Number of meetings attended	Meeting attendance rate	Voting rate	Reason for not attending the meeting
1	Nguyễn Thị Minh Giang	4/4	100%	100%	N/A
2	Phan Tấn Thư	4/4	100%	100%	N/A

SUPERVISORY ACTIVITIES OF THE AUDIT COMMITTEE FOR THE BOARD OF DIRECTORS, MANAGEMENT BOARD, AND SHAREHOLDERS:

Oversight of the Company's operations to ensure compliance with legal requirements and internal management regulations.

Review of the Company's transactions involving internal and related parties, and provision of recommendations to the Executive Board for the establishment of regulations to enhance control and compliance with Company policies and regulations.

Supervision of information disclosure practices in accordance with regulatory requirements.

Recommendations to the Executive Board for actions aimed at enhancing the internal control and risk management system.

Monitoring of the implementation of the General Director's and Executive Board's 2025 production and business plan.

COORDINATION BETWEEN THE AUDIT COMMITTEE AND THE ACTIVITIES OF THE BOARD OF DIRECTORS, EXECUTIVE BOARD, AND OTHER MANAGERS:

The Audit Committee receives assistance from the Board of Directors, General Director, and Business Executives in carrying out its duties.

Collaboration with the Executive Board to execute the action plan aimed at enhancing the effectiveness of internal control, risk management, and corporate governance in 2025.

Directed the Internal Audit to implement the 2025 internal audit plan. The Audit Committee held quarterly meetings with the Executive Board to discuss the results of internal audit activities.

SUBCOMMITTEE ON STRATEGY

Established under Decision No. 1066/QĐ-HĐQT dated June 27, 2024, the Subcommittee on Strategy has the following functions and responsibilities:

FUNCTIONS

Develop and monitor the implementation of the Company's short-term, medium-term and long-term strategies.

RESPONSIBILITIES

- Take charge of developing the Company's short-term, medium-term and long-term development strategies, including but not limited to strategies on human resources, salaries; digitalization; standardization of management systems; market development, etc.
- Periodically review the objectives, tasks, and action plans in the Strategy and make adjustments if necessary.
- Monitor the implementation of the Company's strategic goals.

In 2025, the Strategy Subcommittee effectively fulfilled its role in monitoring, supervising, and providing strategic direction for the Company's key activities. Accordingly, the Subcommittee regularly monitored and assessed the implementation of the EU-GMP projects and issued timely guidance, thereby supporting the Executive Management in controlling progress and aligning implementation activities with the established objectives.

In addition, the Strategy Subcommittee directed the Executive Management to implement a number of critical initiatives, including the development and training of the succession workforce; assessment of the current situation and proposal of solutions to accelerate drug research and registration; and formulation of a plan to reorganize the branch network following the consolidation of administrative units. With

respect to succession training, the Company completed the review and identification of the succession candidate list; based on this, a detailed training plan and training programs will be developed and implemented in 2026.

Furthermore, the Strategy Subcommittee also directed the implementation of personnel rotation initiatives to enable management and high-potential employees to gain hands-on experience and practical exposure, thereby enhancing management capacity and ensuring continuity and stability of the organizational structure. At the same time, the Subcommittee closely monitored the Company's production and business performance and provided timely guidance, supporting the Executive Management in proactively responding to changes and achieving the approved business objectives and plans.

SUBCOMMITTEE ON INVESTOR RELATIONS

Established under Decision No. 1067/QĐ-HĐQT dated June 27, 2024, the Subcommittee on Investor Relations has the following functions and responsibilities:

FUNCTIONS

Investor relations aims to help shareholders, future investors and related parties such as securities companies, media, experts, analysts understand correctly and accurately the value of Bidiphar, including the current and potential benefits of the company, helping Bidiphar more convenient to mobilize capital and increasing the liquidity of the Bidiphar's stock.

RESPONSIBILITIES

- Change the perception of investors and stakeholders about the current value and development potential of the Company.
- Increase analyst recommendations, increase shareholder structure diversity.
- Reduce negative stock price volatility.
- Manage existing investors.
- Support providing information in a consistent, accurate, appropriate, easy-to-understand, attractive and desired manner to different investors.
- Control information transmission inside and outside the Company.
- Organize seminars for the Board of Directors and the Executive Board to have conversation and share information about the Company's operations directly with shareholders and potential investors beside the meetings of the General Meeting of Shareholders.

In 2025, the Investor Relations (IR) Subcommittee implemented a coordinated program of communication and engagement activities with shareholders and investors, aiming to enhance transparency and the effectiveness of IR activities at Bidiphar. The Company maintained regular information disclosure through IR newsletters and quarterly responses to investor inquiries, while promptly updating information on business results, production and business operations, and key corporate developments via multiple channels, including direct emails, the Company's website, and official communication platforms. In addition, the IR Subcommittee proactively organized and participated in meetings, seminars, direct engagements, and factory visits with various domestic and international investment funds and financial institutions, thereby strengthening information exchange and reinforcing relationships with the investor community.

Through these interactions, the IR Subcommittee

noted investors' particular interest in key matters such as business performance, progress of factory investments, the roadmap for EU-GMP certification, dividend policies, revenue structure and growth, as well as industry and market developments. At the same time, the IR Subcommittee coordinated information exchanges with potential strategic investors based on the execution of non-disclosure agreements (NDAs), focusing on discussions of medium- and long-term strategic cooperation opportunities. Based on feedback from investors, the IR Subcommittee continued to refine its communication efforts by enhancing both the frequency and quality of engagement. These initiatives contributed positively to maintaining investor interest, supporting the stability of the Company's share trading, and were reflected in market capitalization, share liquidity, and foreign ownership indicators during 2025.

COMPENSATION & BONUS INFORMATION AND INTERNAL TRANSACTIONS

REMUNERATION AND BONUS DETAILS

The remuneration of members of the Board of Directors, Executive Board, and Audit Committee is publicly disclosed to meet information requests from shareholders and stakeholders. Principle of remuneration payment:

- The total remuneration and bonus of the Board of Directors is determined by the GMS. The actual remuneration and bonus paid to each member is proposed by the Chairman of the Board to the Board of Directors for approval based on the individual's role, tasks, performance results, to motivate the Board of Directors to lead the company in achieving both short-term and long-term goals.
- The total remuneration and bonus of the Executive Board is from salary, bonus and remuneration from total bonus for the Executive Board determined by the GMS.

Remuneration for 2025: Detailed information regarding the remuneration of members of the Board of Directors, Executive Board, and Audit Committee for the fiscal year ending December 31, 2025, is provided below:

No.	Member of the Board of Directors	Position	Total Remuneration 2024 (Unit: VND)	Total Remuneration 2025 (Unit: VND)	Note
1	Tạ Nam Bình	Chairman of the Board of Directors	650,000,000	968,000,000	-
2	Phạm Thị Thanh Hương	Member of the Board of Directors General Director	3,872,050,000	8,334,958,642	In 2025, the Executive Board received bonus payments for the years 2022, 2023, and 2024.
3	Nguyễn Ngọc Dũng	Member of the Board of Directors Vice General Director	3,146,191,596	5,038,977,580	In 2025, the Executive Board received bonus payments for the years 2022, 2023, and 2024.
4	Nguyễn Tiến Hải	Non-Executive members of the Board of Directors	750,000,000	667,000,000	-
5	Trương Thanh Liêm	Non-Executive members of the Board of Directors	1,383,165,000	1,144,406,667	-
6	Nguyễn Thị Minh Giang	Independent members of the Board of Directors	-	817,000,000	-
7	Phan Tấn Thư	Independent members of the Board of Directors	30,000,000	767,000,000	-

No.	Member of the Executive Board	Position	Total Remuneration 2024 (Unit: VND)	Total Remuneration 2025 (Unit: VND)	Note
1	Phạm Thị Thanh Hương	General Director	As above	As above	-
2	Nguyễn Ngọc Dũng	Vice General Director	As above	As above	-
3	Huỳnh Ngọc Oanh	Vice General Director (until 31/12/2024)	2,842,700,000	1,745,500,000	In 2025, the Executive Board received bonus payments for the years 2022, 2023, and 2024.
4	Bành Thị Ngọc Quỳnh	Vice General Director	2,270,030,000	3,441,175,397	In 2025, the Executive Board received bonus payments for the years 2022, 2023, and 2024.

No.	Member of the Audit Committee	Position	Total Remuneration 2024 (Unit: VND)	Total Remuneration 2025 (Unit: VND)	Note
1	Nguyễn Thị Minh Giang	Chairperson	As above	As above	-
2	Phan Tấn Thư	Member	As above	As above	-

COMPENSATION & BONUS INFORMATION AND INTERNAL TRANSACTIONS

INTERNAL TRANSACTIONS DETAILS

Transactions of internal persons and affiliated persons with shares of the company

No.	Transaction executor	Relationship with internal persons	Number of shares owned at the beginning of the period		Number of shares owned at the end of the period		Reasons for increasing, decreasing (buying, selling, converting, rewarding, etc.)
			Number of shares	Percentage	Number of shares	Percentage	
1	Nguyễn Thị Thùy Linh	Sister in law of Mr Trương Thanh Liêm - Member of the Board of Directors	195,000	0.21%	205,000	0.22%	Buying
2	Trương Công Minh	Brother of Mr Trương Thanh Liêm - Member of the Board of Directors	1,081,249	1.16%	1,006,249	1.06%	Selling
3	Bao Minh Securities Company	Affiliated organization of Mr. Phan Tấn Thư - Board Member.	2,814,500	3.01%	0	0.00%	Selling

Transactions between the company and its affiliated persons or between the company and its major shareholders, internal persons and affiliated persons

No.	Name of organization/ individual	Relationship with the Company	NSH No.*, date of issue, place of issue	Address	Time of transactions with the Company	Resolution No. or Decision No. approved by General Meeting of Shareholders/ Board of Directors (if any, specifying date of issue)	Content, quantity, total value of transaction	Note
1	Bidiphar Trading Co.,LTD	Subsidiary Company/ Affiliated Persons of Internal Persons	ERC No.:4101538232 Date of issue: 22/02/2019 Place of issue: Binh Dinh Province Department of Planning and Investment	No.365 Tran Hung Dao Street, Quy Nhon Ward, Gia Lai	From 01/01/2025 to 31/12/2025	Resolution No.1455/NQ-HĐQT on 30/08/2024 on approving contracts, transactions with Affiliated Persons	Sales: 105,338,885,908 dong Purchases: 54,321,126 dong	N/A
2	Bidiphar Organic Medicine Co.,LTD	Subsidiary Company/ Affiliated Persons of Internal Persons	ERC No.:4101619107 Date of issue: 19/08/2022 Place of issue: Binh Dinh Province Department of Planning and Investment	Hamlet 3, An Toan Ward, Gia Lai	From 01/01/2025 to 31/12/2025	Resolution No.1455/NQ-HĐQT on 30/08/2024 on approving contracts, transactions with Affiliated Persons	Purchases: 657,127,099 dong	N/A
3	Binh Dinh Development Investment Fund	Major shareholder	NSH No.: 1086 QĐ/ UB Date of issue: 08/05/1997	No.181 Le Hong Phong Street, Quy Nhon Ward, Gia Lai	From 01/01/2025 to 31/12/2025	Resolution No.1455/NQ-HĐQT on 30/08/2024 on approving contracts, transactions with Affiliated Persons	Principal Repayment: 16,000,000,000 dong Interest Payment: 3,931,722,000 dong	N/A

CONSOLIDATED FINANCIAL STATEMENT

(FOR THE FISCAL YEAR ENDED DECEMBER 31, 2025)

CONTENT

- GENERAL INFORMATION
- REPORT OF THE MANAGEMENT
- INDEPENDENT AUDITOR'S REPORT
- CONSOLIDATED BALANCE SHEET
- CONSOLIDATED STATEMENT OF INCOME
- CONSOLIDATED STATEMENT OF CASH FLOWS
- NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT

GENERAL INFORMATION

THE COMPANY

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) (“the Company”) was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QD-UBND on 23 June 2010 and the first Enterprise Registration Certificate (“ERC”) No. 4100259564 issued by Department of Planning and Investment (“DPI”) of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14th amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares are listed on the Ho Chi Minh City Stock Exchange (“HOSE”) with trading code as DBD in accordance with License No. 185/QD-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Company are manufacturing and trading in pharmaceutical products and medical equipment.

The Company's registered head office is located at 498 Nguyen Thai Hoc, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has seventeen (17) branches located at other province/cities within Vietnam.

BOARD OF DIRECTORS

The members of the Board of Directors during the year and at the date of this report are:

Mr Ta Nam Binh	Chairman/Independent member
Mr Nguyen Tien Hai	Member
Mrs Pham Thi Thanh Huong	Member
Mr Nguyen Ngoc Dung	Member
Mr Truong Thanh Liem	Member
Mr Phan Tan Thu	Member
Mrs Nguyen Thi Minh Giang	Independent member

INTERNAL AUDIT COMMITTEE UNDER BOARD OF DIRECTORS

The members of the Audit Committee under the Board of Directors during the year and at the date of this report are:

Mrs Nguyen Thi Minh Giang	Chairwoman
Mr Phan Tan Thu	Member

MANAGEMENT

The members of the Management during the year and at the date of this report are:

Mrs Pham Thi Thanh Huong	General Director
Mr Nguyen Ngoc Dung	Deputy General Director
Mrs Banh Thi Ngoc Quynh	Deputy General Director

LEGAL REPRESENTATIVE

The legal representative of the Company during the year and at the date of this report is **Ms Pham Thi Thanh Huong**.

AUDITOR

The auditor of the Company is **Ernst & Young Vietnam Limited**.

REPORT OF THE MANAGEMENT

The management of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) (“the Company”) is pleased to present this report and the consolidated financial statements of the Company and its subsidiaries (collectively referred to as “the Group”) for the year ended 31 December 2025.

THE MANAGEMENT’S RESPONSIBILITY IN RESPECT OF THE CONSOLIDATED FINANCIAL STATEMENTS

The management is responsible for the consolidated financial statements of each financial year which give a true and fair view of the consolidated financial position of the Group and of the results of its consolidated operations and its consolidated cash flows for the year. In preparing those consolidated financial statements, management is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the consolidated financial statements; and
- Prepare the consolidated financial statements on the going concern basis unless it is inappropriate to presume that the Group will continue its business.

The management is responsible for ensuring that proper accounting records are kept which disclose, with reasonable accuracy at any time, the consolidated financial position of the Group and to ensure that the accounting records comply with the applied accounting system. It is also responsible for safeguarding the assets of the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The management confirmed that it has complied with the above requirements in preparing the accompanying consolidated financial statements.

STATEMENT BY THE MANAGEMENT

The management does hereby state that, in its opinion, the accompanying consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 31 December 2025 and of the consolidated results of its operations and its consolidated cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements.

For and on behalf of the management:



Pham Thi Thanh Huong
General Director

Gia Lai Province, Vietnam
20 March 2026

Reference: 12315209/68628197-HN

INDEPENDENT AUDITOR’S REPORT

To: The Shareholders of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR)

We have audited the consolidated financial statements of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) (“the Company”) and its subsidiaries (collectively referred to as “the Group”), as prepared on 20 March 2026 and set out on pages 6 to 40, which comprise the consolidated balance sheet as at 31 December 2025, the consolidated income statement and the consolidated cash flow statement for the year then ended and the notes thereto.

The management’s responsibility

The Group’s management is responsible for the preparation and true and fair presentation of these consolidated financial statements in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements, and for such internal control as management determines is necessary to enable the preparation and presentation of the consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors’ responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditors consider internal control relevant to the Group’s preparation and true and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group’s internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements give a true and fair view, in all material respects, of the consolidated financial position of the Group as at 31 December 2025, and of the consolidated results of its operations and its consolidated cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to the preparation and presentation of the consolidated financial statements.

Ernst & Young Vietnam Limited



Pham Thi Cam Tu
Deputy General Director
Audit Practicing Registration Certificate
No: 2266-2023-004-1

Ho Chi Minh City, Vietnam
20 March 2026



Trần Thanh Thúy
Auditor
Audit Practicing Registration Certificate
No: 3076-2024-004-1

CONSOLIDATED BALANCE SHEET

(As at 31 December 2025)

VND

CODE	ASSETS	NOTES	ENDING BALANCE	BEGINNING BALANCE
100	A. CURRENT ASSETS		1,480,040,155,611	1,476,280,617,777
110	I. Cash and cash equivalents	4	202,783,644,602	314,198,731,825
111	1.Cash		54,783,644,602	56,698,731,825
112	2.Cash equivalents		148,000,000,000	257,500,000,000
120	II. Short-term investments		409,201,393,300	124,421,158,600
121	1.Held-for-trading securities		1,393,300	1,393,300
123	2.Held-to-maturity investments	5	409,200,000,000	124,419,765,300
130	III. Current accounts receivable		481,814,409,349	520,222,627,983
131	1.Short-term trade receivables	6.1	495,347,003,230	504,877,324,434
132	2.Short-term advances to supplier	6.2	40,788,245,884	76,498,728,383
136	3.Other short-term receivables	7	8,933,170,440	6,918,534,026
137	4.Provision for doubtful short-term receivables	8	(63,254,010,205)	(68,071,958,860)
140	IV. Inventories	9	366,109,634,763	505,380,962,218
141	1.Inventories		397,619,665,024	532,336,906,627
149	2.Provision for obsolete inventories		(31,510,030,261)	(26,955,944,409)
150	V. Other current assets		20,131,073,597	12,057,137,151
151	1.Short-term prepaid expenses	10	8,972,511,923	8,653,554,344
152	2.Value-added tax deductible		10,800,145,333	1,895,670,328
153	3.Tax and other receivables from the State	16	358,416,341	1,507,912,479
200	B. NON-CURRENT ASSETS		1,116,173,559,655	787,925,914,939
220	I. Fixed assets		354,226,404,219	337,549,679,184
221	1.Tangible fixed assets	11	271,987,287,244	280,725,745,444
222	Cost		849,656,422,084	810,661,849,768
223	Accumulated depreciation		(577,669,134,840)	(529,936,104,324)
227	2.Intangible fixed assets	12	82,239,116,975	56,823,933,740
228	Cost		103,210,817,688	76,110,993,392
229	Accumulated amortization		(20,971,700,713)	(19,287,059,652)
240	II. Long-term asset in progress		540,162,602,121	233,459,463,621
242	1.Construction in progress	13	540,162,602,121	233,459,463,621
250	III. Long-term investments	14	163,965,069,911	164,241,726,585
252	1.Investments in an associate		162,451,534,940	162,728,191,614
253	2.Investments in other entities		3,513,534,971	3,513,534,971
254	3.Provision for diminution in value of long-term investments		(2,000,000,000)	(2,000,000,000)
260	IV. Other long-term assets		57,819,483,404	52,675,045,549
261	1.Long-term prepaid expenses	10	42,059,071,473	39,382,942,604
262	2.Deferred tax assets	29.3	15,760,411,931	13,292,102,945
270	TOTAL ASSETS		2,596,213,715,266	2,264,206,532,716

VND

CODE	ASSETS	NOTES	ENDING BAL-ANCE	BEGINNING BAL-ANCE
300	C. LIABILITIES		860,234,784,589	603,065,716,999
310	I. Current liabilities		587,673,892,225	460,154,613,654
311	1. Short-term trade payables	15.1	217,824,029,248	160,802,900,081
312	2. Short-term advances from customers	15.2	15,454,643,486	15,976,752,341
313	3. Statutory obligations	16	53,527,734,518	27,372,531,041
314	4. Payables to employees		93,472,143,498	78,337,451,082
315	5. Short-term accrued expenses	17	26,188,049,685	19,823,557,873
319	6. Other short-term payables	18	9,881,257,721	8,681,086,654
320	7. Short-term loans	19	43,214,775,628	35,913,500,637
322	8. Bonus and welfare fund	20	128,111,258,441	113,246,833,945
330	II. Non-current liabilities		272,560,892,364	142,911,103,345
338	1. Long-term loans	19	132,000,000,000	28,000,000,000
342	2. Other long-term provisions	3.11	7,790,562,288	7,267,083,725
343	3. Scientific and technological development fund	21	132,770,330,076	107,644,019,620
400	D. OWNERS' EQUITY		1,735,978,930,677	1,661,140,815,717
410	I. Capital	22.1	1,733,736,746,936	1,658,732,981,612
411	1. Share capital		945,293,470,000	935,938,470,000
411a	- Ordinary shares with voting rights		945,293,470,000	935,938,470,000
412	2. Share premium		20,921,442,000	20,921,442,000
415	3. Treasury shares		(1,952,796,558)	(1,952,796,558)
417	4. Foreign exchange differences reserve		8,804,077,510	4,790,551,103
418	5. Investment and development fund		230,880,981,458	201,686,964,998
421	6. Undistributed earnings		529,789,572,526	497,348,350,069
421a	- Undistributed earnings by the end of prior year		307,961,246,104	288,210,068,687
421b	- Undistributed earnings of the year		221,828,326,422	209,138,281,382
430	II. Other funds	23	2,242,183,741	2,407,834,105
431	1. Subsidized fund		719,369,206	38,936,237
432	2. Fund for fixed assets in use		1,522,814,535	2,368,897,868
440	TOTAL LIABILITIES AND OWNERS' EQUITY		2,596,213,715,266	2,264,206,532,716

Gia Lai Province, Vietnam
20 March 2026


Le Thi Kieu My
Preparer


Do Huy Phuong
Chief Accountant




Pham Thi Thanh Huong
General Director

CONSOLIDATED INCOME STATEMENT

(For the year ended 31 December 2025)

VND

CODE	ITEMS	NOTES	CURRENT YEAR	PREVIOUS YEAR
01	1. Revenues from sale of goods and rendering of services	24.1	1,946,612,659,958	1,817,259,164,083
02	2. Deductions	24.1	(81,233,070,327)	(89,710,776,512)
10	3. Net revenues from sale of goods and rendering of services	24.1	1,865,379,589,631	1,727,548,387,571
11	4. Cost of goods sold and services rendered	25	(981,000,795,265)	(894,975,138,716)
20	5. Gross profits from sale of goods and rendering of service		884,378,794,366	832,573,248,855
21	6. Finance income	24.2	25,189,164,182	13,359,148,358
22	7. Finance expenses	27	(14,617,224,889)	(16,928,510,396)
23	<i>In which: Interest expense</i>		<i>(3,846,557,387)</i>	<i>(4,058,137,920)</i>
24	8. Shares of profit from an associate	14.1	12,280,174,884	27,063,089,931
25	9. Selling expenses	26	(418,308,462,079)	(404,195,096,035)
26	10. General and administrative expenses	26	(139,794,488,425)	(122,785,668,843)
30	11. Operating profit		349,127,958,039	329,086,211,870
31	12. Other income		767,103,104	1,077,222,036
32	13. Other expenses		(3,813,024,763)	(5,027,909,575)
40	14. Other losses		(3,045,921,659)	(3,950,687,539)
50	15. Accounting profit before tax		346,082,036,380	325,135,524,331
51	16. Current corporate income tax expense	29.1	(56,610,180,760)	(55,276,507,052)
52	17. Deferred tax income	29.3	2,468,308,986	5,322,931,908
60	18. Net profit after tax		291,940,164,606	275,181,949,187

VND

CODE	ITEMS	NOTES	CURRENT YEAR	PREVIOUS YEAR
61	19. Net profit after tax attributable to shareholders of the parent		291,940,164,606	275,181,949,187
70	20. Basic earnings per share	22.5	2,674	2,530
71	21. Diluted earnings per share	22.5	2,674	2,530

Gia Lai Province, Vietnam
20 March 2026



Le Thi Kieu My
Preparer



Do Huy Phuong
Chief Accountant



Pham Thi Thanh Huong
General Director

CONSOLIDATED CASH FLOW STATEMENT

(For the year ended 31 December 2025)

VND

CODE	ITEMS	NOTES	CURRENT YEAR	PREVIOUS YEAR
	I. CASH FLOWS FROM OPERATING ACTIVITIES			
01	Accounting profit before tax		346,082,036,380	325,135,524,331
	Adjustments for:			
02	Depreciation and amortization		51,021,340,822	48,112,079,145
03	Provisions		259,615,760	17,753,867,873
04	Foreign exchange losses arisen from revaluation of monetary accounts denominated in foreign currency		103,878,871	245,498,185
05	Profits from investing activities		(32,316,019,304)	(38,668,096,477)
06	Interest expense	27	3,846,557,387	4,058,137,920
07	Other adjustments		27,920,976,714	23,237,816,553
08	Operating profit before changes in working capita		396,918,386,630	379,874,827,530
09	Decrease (increase) in receivables		407,602,289	(16,554,126,145)
10	Decrease (increase) in inventories		134,717,241,603	(33,973,935,685)
11	Increase in payables		133,042,465,086	11,570,263,662
12	Increase in prepaid expenses		(2,995,086,448)	(1,835,431,205)
14	Interest paid		(3,706,362,387)	(4,190,082,920)
15	Corporate income tax paid	16	(24,728,641,081)	(63,607,032,235)
16	Other cash inflows for operating activities		2,870,749,417	2,474,736,062
17	Other cash outflows for operating activities		(21,339,003,042)	(9,028,940,537)
20	Net cash flows from operating activities		615,187,352,067	264,730,278,527
	II. CASH FLOWS FROM INVESTING ACTIVITIES			
21	Purchase and construction of fixed assets		(408,573,235,412)	(148,745,141,676)
23	Bank term deposits		(333,700,000,000)	(109,956,292,800)
24	Collection of bank term deposits		48,919,765,300	224,593,126,650
27	Interest and dividend received		31,729,947,759	11,124,335,085
30	Net cash flows used in investing activities		(661,623,522,353)	(22,983,972,741)

VND

CODE	ITEMS	NOTES	CURRENT YEAR	PREVIOUS YEAR
	III. CASH FLOWS FROM FINANCING ACTIVITIES			
31	Capital contribution	22.2	9.355.000.000	-
33	Drawdown of borrowings	19	259.894.808.772	60,379,701,637
34	Repayment of borrowings	19	(148.593.533.781)	(75,733,320,497)
36	Dividend paid	22.2	(185.628.543.075)	(9,933,200)
40	Net cash flows used in financing activities		(64,972,268,084)	(15,363,552,060)
50	Net (decrease) increase in cash and cash equivalent		(111,408,438,370)	226,382,753,726
60	Cash and cash equivalents at beginning of year		314,198,731,825	87,837,172,191
61	Impact of exchange rate fluctuation		(6,648,853)	(21,194,092)
70	Cash and cash equivalents at end of year	4	202,783,644,602	314,198,731,825

Gia Lai Province, Vietnam
20 March 2026



Le Thi Kieu My
Preparer



Do Huy Phuong
Chief Accountant




Pham Thi Thanh Huong
General Director

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENT

(As at 31 December 2025 and for the year then ended)

1. CORPORATE INFORMATION

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (BIDIPHAR) (“the Company”) was formerly known as Binh Dinh Pharmaceutical and Medical Equipment Company which was transformed from a state-owned enterprise into a one-member limited liability company owned by People's Committee of Binh Dinh Province in accordance with the Decision No. 264/QD-UBND on 23 June 2010 and the first Enterprise Registration Certificate (“ERC”) No. 4100259564 issued by Department of Planning and Investment (“DPI”) of Binh Dinh Province on 1 September 2010. Since March 2014, the Company has changed its legal ownership form from one-member limited liability company to joint stock company according to the second amended ERC No. 4100259564 issued by the DPI of Binh Dinh Province on 1 March 2014 and 14th amended ERC issued by the Department of Enterprise and Collective Economy under the Department of Finance of Gia Lai Province on 11 September 2025.

The Company's shares were listed on the Ho Chi Minh City Stock Exchange (“HOSE”) with trading code as DBD in accordance with License No. 185/QD-SGDHCM issued by the HOSE on 24 May 2018.

The principal activities of the Group are manufacturing and trading in pharmaceutical products and medical equipment.

The Group's normal course of business cycle is 12 months.

The Company's registered head office is located at 498 Nguyen Thai Hoc, Quy Nhon Nam Ward, Gia Lai Province, Vietnam. In addition, the Company also has seventeen (17) branches located at other province/cities within Vietnam.

The number of the Group's employees as at 31 December 2025 was 1,375 employees (31 December 2024: 1,368 employees).

Corporate structure

As at 31 December 2025, the Group's corporate structure included two (2) subsidiaries and an associate. Details are as follows:

Name	Head office	Business activities	Beginning and ending balances	
			Ownership (%)	Voting rights (%)
Subsidiaries				
(1) Bidiphar Trading Company Limited	Gia Lai Province	Wholesale and retail sale of medicines, medicinal herbs, medical equipment	100,00	100,00
(2) Bidiphar Organic Medicine Limited Company	Gia Lai Province	Production of medicines, medicinal chemicals and medicinal herbs	100,00	100,00
Associate				
(1) Bidiphar Rubber Joint Stock Company	Gia Lai Province	Planting, mining, processing and trading rubber latex	33,58	33,58

2. BASIS OF PREPARATION

2.1 Accounting standards and system

The consolidated financial statements of the Group expressed in Vietnam dong (“VND”), are prepared in accordance with the Vietnamese Enterprise Accounting System and other Vietnamese Accounting Standards issued by the Ministry of Finance as per:

- Decision No. 149/2001/QD-BTC dated 31 December 2001 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 1);
- Decision No. 165/2002/QD-BTC dated 31 December 2002 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 2);
- Decision No. 234/2003/QD-BTC dated 30 December 2003 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 3);
- Decision No. 12/2005/QD-BTC dated 15 February 2005 on the Issuance and Promulgation of Six Vietnamese Accounting Standards (Series 4); and
- Decision No. 100/2005/QD-BTC dated 28 December 2005 on the Issuance and Promulgation of Four Vietnamese Accounting Standards (Series 5).

Accordingly, the accompanying consolidated financial statements, including their utilization are not designed for those who are not informed about Vietnam's accounting principles, procedures and practices and furthermore are not intended to present the consolidated financial position and the consolidated results of operations and the consolidated cash flows of the Group in accordance with accounting principles and practices generally accepted in countries other than Vietnam.

2.2 Applied accounting documentation system

The Group's applied accounting documentation system is the Computerised based.

2.3 Fiscal year

The Group's fiscal year applicable for the preparation of its consolidated financial statements starts on 1 January and ends on 31 December.

2.4 Accounting currency

The consolidated financial statements are prepared in VND which is also the Group's accounting currency.

2.5 Basic of consolidation

The consolidated financial statements comprise the separate financial statements of the Company and its subsidiaries for the year ended 31 December 2025.

Subsidiaries are fully consolidated from the date of acquisition, being the date on which the Group obtains control, and continued to be consolidated until the date that such control ceases.

The financial statements of the subsidiary are prepared for the same reporting year as the parent company, using consistent accounting policies.

All intra-company balances, income and expenses and unrealized gains or losses resulted from intra-company transactions are eliminated in full.

Non-controlling interests represent the portion of profit or loss and net assets not held by the Group and are presented separately in the consolidated income statement and within equity in the consolidated balance sheet.

Impact of change in the ownership interest of a subsidiary, without a loss of control, is recorded in undistributed earnings.

2. BASIS OF PREPARATION *(continued)*

2.6 Accounting regulation issued but not yet effective

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC providing guidance on the enterprise accounting regime ("Circular 99"), replacing Circular No. 200/2014/TT-BTC providing guidance on the enterprise accounting regime issued by the Ministry of Finance on 22 December 2014 and several other related regulations. Circular 99 takes effect from 1 January 2026 and applies to enterprises with a financial year beginning on or after 1 January 2026.

The Group is in the process of assessing the impact of Circular 99 on the preparation and presentation of its consolidated financial statements and will implement Circular 99 for the financial year ending 31 December 2026.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3.1 Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash in banks and short-term, highly liquid investments with an original maturity of less than three months that are readily convertible into known amounts of cash and that are subject to an insignificant risk of changes in value.

3.2 Inventories

Inventories are measured at their historical costs. The cost of inventories comprises costs of purchase, costs of conversion (including raw materials, direct labor cost, other directly related cost, manufacturing general overheads allocated based on the normal operating capacity) incurred in bringing the inventories to their present location and condition.

In case the net realizable value is lower than the original price, it must be calculated according to the net realizable value. Net realisable ("NRV") value represents the estimated selling price in the ordinary course of business less the estimated costs to complete and the estimated costs necessary to make the sale.

The perpetual method is used to record inventories, which are valued as follows:

Raw materials, tool and supplies and merchandis.	- Actual cost on a weighted average basis.
Work-in-process and finished goods.	- Cost of finished goods and work-in-process on a weighted average basis.

Provision for obsolete inventories

An inventory provision is created for the estimated loss arising due to the impairment of value (through diminution, damage, obsolescence, etc.) of raw materials, finished goods, merchandise and other inventories owned by the Group, based on appropriate evidence of impairment available at the balance sheet date.

Increases or decreases to the provision balance are recorded into the cost of goods sold account in the consolidated income statement. When inventories are expired, obsolescence, damage or become useless, the difference between the provision previously made and the historical cost of inventories are included in the consolidated income statement.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

3.3 Receivables

Receivables are presented in the consolidated balance sheet at the carrying amounts due from customers and other debtors, after the provision for doubtful receivables.

The provision for doubtful receivables represents amounts of outstanding receivables at the balance sheet date which are doubtful of being recovered. Increases or decreases to the provision balance are recorded as general and administrative expense in the consolidated income statement. When bad debts are determined as unrecoverable and accountant writes off those bad debts, the differences between the provision for doubtful receivables previously made and historical cost of receivables are included in the consolidated income statement.

3.4 Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation.

The cost of a tangible fixed asset comprises its purchase price and any directly attributable costs of bringing the tangible fixed asset to working condition for its intended use and the costs of dismantling and removing the asset and restoring the site on which it is located, if any. Expenditures for additions, improvements and renewals are added to the carrying amount of the assets and expenditures for maintenance and repairs are charged to the consolidated income statement as incurred.

When tangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

3.5 Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated amortization.

The cost of an intangible fixed asset comprises its purchase price and any directly attributable costs of preparing the intangible fixed asset for its intended use. Expenditures for additions, improvements are added to the carrying amount of the assets and other expenditures are charged to the consolidated income statement as incurred.

When intangible fixed assets are sold or retired, any gain or loss resulting from their disposal (the difference between the net disposal proceeds and the carrying amount) is included in the consolidated income statement.

Land used rights

Land use rights are recorded as intangible fixed assets representing the value of the rights to use the lands acquired by the Group. The advance payment for land rental, of which the land lease contracts, and Land use rights certificate being issued, are recorded as intangible fixed asset according to Circular No. 45/2013/TT-BTC issued by the Ministry of Finance on 25 April 2013 guiding the management, use and depreciation of fixed assets ("Circular 45").

The useful life of land use rights are assessed as either definite or indefinite. Accordingly, the land use rights with definite useful life representing the land lease are amortized over the lease term while the land use rights with indefinite useful lives is not amortized.

3.6 Depreciation and amortization

Depreciation of tangible fixed assets and amortization of intangible fixed assets are calculated on a straight-line basis over the estimated useful life of each asset as follows:

Buildings and structures	4 - 43 years
Machinery and equipment	4 - 12 years
Means of transportation	4 - 10 years
Office equipment	4 - 10 years
Land use rights	50 years
Computer software	4 - 10 years

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

3.7 Construction in progress

Construction in progress represents the costs of acquiring new assets that have not yet been fully installed or the costs of construction that have not yet been fully completed. Construction in progress is stated at cost, which includes all necessary costs to construct, repair, renovate, expand, or re-equip the projects with technologies, such as construction costs, tools and equipment costs, project management costs, construction consulting costs, and borrowing costs that are eligible for capitalization.

Construction in progress will be transferred to the appropriate fixed asset account when these assets are fully installed or the construction project is fully completed, and depreciation of these assets will commence when they are ready for their intended use.

Construction costs are recognized as expenses when such costs do not meet the conditions to be recognized as fixed assets.

3.8 Borrowing costs

Borrowing costs consist of interest and other costs that the Group incurs in connection with the borrowing of funds.

Borrowing costs that are directly attributable to the acquisition, construction or production of an asset that necessarily take a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the respective asset.

3.9 Leased assets

The determination of whether an arrangement is, or contains a lease is based on the substance of the arrangement at inception date and requires an assessment of whether the fulfilment of the arrangement is dependent on the use of a specific asset and the arrangement conveys a right to use the asset.

A lease is classified as a finance lease whenever the terms of the lease transfer substantially all the risks and rewards of ownership of the asset to the lessee. All other leases are classified as operating leases.

Where the Group is the lessee

Rentals under operating leases are charged to the consolidated income statement on a straight-line basis over the term of the lease.

3.10 Prepaid expenses

Prepaid expenses are reported as short-term or long-term prepaid expenses on the consolidated balance sheet and amortized over the year for which the amounts are paid or the year in which economic benefits are generated in relation to these expenses.

3.11 Accrual for severance pay

The severance pay to employee is accrued at the end of each reporting year for employees who have been worked for more than 12 months at the Group. The accrued amount is calculated at the rate of one-half of the average monthly salary for each year of service qualified for severance pay in accordance with the Labor Code and related implementing guidance. The average monthly salary used in this calculation is adjusted at the end of each reporting year following the average monthly salary of the last 6-month period up to the reporting date. Increases or decreases to the accrued amount other than actual payment to employee will be taken to the consolidated income statement.

This accrued severance pay is used to settle the termination allowance to be paid to employee upon termination of their labour contract following Article 46 of the Labor Code.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES *(continued)*

3.12 Business combinations

Business combinations are accounted for using the purchase method. The cost of a business combination is measured as the fair value of assets given, equity instruments issued and liabilities incurred or assumed at the date of exchange plus any costs directly attributable to the business combination. Identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured initially at fair values at the date of business combination.

3.13 Investments

Investment in an associate

The Group's investment in its associate is accounted for using the equity method of accounting. An associate is an entity in which the Group has significant influence that is neither subsidiaries nor joint ventures. The Group generally deems they have significant influence if they have over 20% of the voting rights.

Under the equity method, the investment is carried in the consolidated balance sheet at cost plus post-acquisition changes in the Group's share of net assets of the associates. Goodwill arising on acquisition of the associate is included in the carrying amount of the investment. Goodwill is not amortized and subject to annual review for impairment. The consolidated income statement reflects the share of the post-acquisition results of operation of the associate.

The share of post-acquisition profit (loss) of the associate is presented on face of the consolidated income statement and its share of post-acquisition movements in reserves is recognized in reserves. The cumulative post-acquisition movements are adjusted against the carrying amount of the investment. Dividend/profit sharing receivable from associate reduces the carrying amount of the investment.

The financial statements of the associate are prepared for the same reporting year and use the same accounting policies as the Group. Where necessary, adjustments are made to bring the accounting policies in line with those of the Group.

Held-for-trading securities and investments in other entities

Held-for-trading securities and investments in other entities are stated at their acquisition costs.

Provision for diminution in value of the investments

Provision for diminution in value of the investment is made when there are reliable evidences of the diminution in value of those investments at the balance sheet date.

Increases or decreases to the provision balance are recorded as finance expense in the consolidated income statement.

Held-to-maturity investments

Held-to-maturity investments are stated at their acquisition costs. After initial recognition, held-to-maturity investments are measured at recoverable amount. Any impairment loss incurred is recognized as expense in the consolidated financial statements and deducted against the value of such investments.

3.14 Payables and accruals

Payables and accruals are recognized for amounts to be paid in the future for goods and services received, whether or not billed to the Group.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

3.15 Foreign currency transactions

Transactions in currencies other than the Group's reporting currency of VND are recorded at the actual transaction exchange rates at transaction dates which are determined as follows:

- Transactions resulting in receivables are recorded at the buying exchange rates of the commercial banks designated for collection; and
- Transactions resulting in liabilities are recorded at the selling exchange rates of the commercial banks designated for payment.

At the end of the year, monetary balances denominated in foreign currencies are translated at the actual transaction exchange rates at the balance sheet dates which are determined as follows:

- Monetary assets are translated at buying exchange rate of the commercial bank where the Group conducts transactions regularly; and
- Monetary liabilities are translated at selling exchange rate of the commercial bank where the Group conducts transactions regularly.

All foreign exchange differences incurred are taken to the consolidated income statement.

3.16 Share capital

Ordinary shares

Ordinary shares with voting right are recognised at par value.

Share premium

Share premium is the difference between the par value and the issuance price of the shares, minus the actual expenses incurred for the issuance of the shares.

Treasury shares

Own equity instruments which are reacquired (treasury shares) are recognised at cost and deducted from equity. No gain or loss is recognised in the consolidated income statement upon purchase, sale, issue or cancellation of the Company's own equity instruments.

3.17 Appropriation of net profits

Net profit after tax (excluding negative goodwill arising from a bargain purchase) is available for appropriation to shareholders after approval in the annual general meeting, and after making appropriation to reserve funds in accordance with the Company's Charter and Vietnam's regulatory requirements.

The Group maintains the following reserve funds which are appropriated from the Group's net profit as proposed by the Board of Directors and subject to approval by shareholders at the annual general meeting:

Investment and development fund

This fund is set aside for use in the Group's expansion of its operation or of in-depth investments.

Bonus and welfare fund

This fund is comprised of bonus, welfare fund for employees and bonus fund for the management, which is set aside for the purpose of pecuniary rewarding and encouraging, common benefits and improvement of the employees' benefits. This fund is presented as a liability on the consolidated balance sheet.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

3.17 Appropriation of net profits (continued)

Dividends

Dividends proposed by the Group's Board of Directors are classified as an allocation of undistributed earnings within the equity section of the consolidated balance sheet, until they have been approved by the Group's shareholders at the Annual General Meeting. When these dividends have been approved by the shareholders and declared, they are recognized as a liability in the consolidated balance sheet.

3.18 Earnings per share

Basic earnings per share amount is computed by dividing net profit attributable to ordinary equity holders of the Group (after adjusting for the bonus and welfare fund) by the weighted average number of ordinary shares outstanding during the year.

Diluted earnings per share amounts are calculated by dividing the net profit after tax attributable to ordinary equity holders of the Group by the weighted average number of ordinary shares outstanding during the year plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

3.19 Revenue recognition

Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable, excluding trade discount, rebate and sales return. The following specific recognition criteria must also be met before revenue is recognized:

Sale of goods

Revenue is recognized when the significant risks and rewards of ownership of the goods have passed to the buyer, usually upon the delivery of the goods.

Rendering of services

Revenue is recognized when the services have been performed and completed.

Interest income

Interest is recognized on an accrual basis based on the time and actual interest rate for each period.

Dividend and profit distribution income

Dividend and profit distribution income are recognized when Group is entitled to receive dividends or when the Group are entitled to receive profits from its capital contributions.

3.20 Taxation

Current income tax

Current income tax assets and liabilities for the current and prior years are measured at the amount expected to be paid to or recovered from the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted as at the balance sheet date.

Current income tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the current deferred income tax is also dealt with in equity.

Current income tax assets and liabilities are offset when there is a legally enforceable right for the Group to set off current income tax assets against current income tax liabilities and when the Group intend to settle its current income tax assets and liabilities on a net basis.

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)

3.20 Taxation (continued)

Deferred tax

Deferred tax is provided using the liability method on temporary differences at the balance sheet date between the tax base of assets and liabilities and their carrying amount for financial reporting purpose.

Deferred tax liabilities are recognized for all taxable temporary differences. Deferred tax assets are recognized for all deductible temporary differences, carried forward unused tax credit and unused tax losses, to the extent that it is probable that taxable profits will be available against which deductible temporary differences, carried forward unused tax credit and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Previously unrecognized deferred tax assets are re-assessed at each balance sheet date and are recognized to the extent that it has become probable that future taxable profit will allow the deferred tax assets to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized, or the liability is settled based on tax rates and tax laws that have been enacted at the balance sheet date.

Deferred tax is charged or credited to the consolidated income statement, except when it relates to items recognized directly to equity, in which case the deferred tax is also dealt with in the equity account.

Deferred tax assets and liabilities are offset when there is a legally enforceable right for the Group to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority on the same taxable entity or when the Group intends either to settle current tax liabilities and assets on a net basis or to realize the assets and settle the liabilities simultaneously, in each future year in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

3.21 Related parties

Parties are considered to be related parties of the Group if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions, or when the Group and other party are under common control or under common significant influence. Related parties can be enterprise or individual, including close members of the family of any such individual.

3.22 Segment reporting

A segment is a component determined separately by the Group which is engaged in providing products or related services (business segment), or providing products or services in a particular economic environment (geographical segment), that is subject to risks and returns that are different from those of other segments. As the Company's revenue and profit are derived mainly from manufacturing and trading pharmaceutical products in Vietnam while other sources of revenue are not material as a whole, management accordingly believes that the Group operates in a sole business segment of manufacturing and trading pharmaceutical products within a single geographical segment. Therefore, no further segmental information is required to be presented.

4. CASH AND CASH EQUIVALENTS

	Ending balance	Beginning balance
Cash on hand	1,545,696,148	1,496,871,788
Cash in banks	53,237,948,454	55,201,860,037
Time deposits at banks	148,000,000,000	257,500,000,000
TOTAL	202,783,644,602	314,198,731,825

5. SHORT-TERM HELD-TO-MATURITY INVESTMENTS

Held-to-maturity investments represent term deposits at the commercial banks with the original maturity of more than three (3) months and the remaining maturity not exceeding twelve (12) months from the financial year-end and earn interest at the applicable bank deposit rates.

6. SHORT-TERM TRADE RECEIVABLES AND ADVANCE TO SUPPLIES

6.1 Short-term trade receivables

	Ending balance	Beginning balance
South-East Investment Development Technology Company Limited	45,131,856,249	45,131,856,249
Others	450,215,146,981	459,745,468,185
TOTAL	495,347,003,230	504,877,324,434
<i>Provision for doubtful short-term receivables (Note 8)</i>	(59,624,672,966)	(64,418,817,801)
NET	435,722,330,264	440,458,506,633

6.2 Short-term advances to suppliers

	Ending balance	Beginning balance
Viet Son Technology Joint Stock Company	4,434,147,686	-
Dong A Refrigeration and Electrical Engineering Joint Stock Company	3,531,236,442	267,979,046
Dong Nam Company Limited	1,091,279,592	1,091,279,592
Truiking Technology Limited	584,887,448	12,995,306,236
Tofflon Science and Technology Group Company Limited	-	36,272,301,000
Others	31,146,694,716	25,871,862,509
TOTAL	40,788,245,884	76,498,728,383
<i>Provision for doubtful short-term receivables (Note 8)</i>	(1,347,475,772)	(1,371,279,592)
NET	39,440,770,112	75,127,448,791

7. OTHER SHORT-TERM RECEIVABLES

	VND	
	Ending balance	Beginning balance
Accrued interest income	5,065,236,988	2,468,562,327
Advance to employees	349,414,190	932,928,777
Others	3,518,519,262	3,517,042,922
TOTAL	8,933,170,440	6,918,534,026
Provision for doubtful short-term receivables (Note 8)	(2,281,861,467)	(2,281,861,467)
NET	6,651,308,973	4,636,672,559

8. PROVISION

8.1 Provision for short-term doubtful receivables

	VND	
	Current year	Previous year
Beginning balance	(68,071,958,860)	(69,378,783,874)
Add: Provision made during the year	-	(4,571,999,735)
Less: Reversal of provision during the year	4,817,948,655	5,878,824,749
Ending balance	(63,254,010,205)	(68,071,958,860)

8.2 Overdue debts

	Debtors			VND
	South-East Investment Development Technology Company Limited	Kien Tao Limited Company	Other customers	Total
Ending balance				
Cost	45,895,444,249	11,560,756,445	8,247,865,628	65,704,066,322
Provision	(45,895,444,249)	(11,560,756,445)	(5,797,809,511)	(63,254,010,205)
Net amount	-	-	2,450,056,117	2,450,056,117
Beginning balance				
Cost	46,986,723,841	12,339,449,445	13,983,805,762	73,309,979,048
Provision	(46,986,723,841)	(12,339,449,445)	(8,745,785,574)	(68,071,958,860)
Net amount	-	-	5,238,020,188	5,238,020,188

9. INVENTORIES

	Ending balance		Beginning balance		VND
	Cost	Provision	Cost	Provision	
Raw materials	232,926,577,547	(30,381,868,122)	269,060,649,045	(21,907,801,829)	
Finished goods	110,681,721,156	(949,155,812)	184,478,440,062	(3,124,185,961)	
Goods in transit	21,005,148,055	-	40,395,223,790	-	
Work in progress	27,386,165,637	-	28,947,218,521	-	
Merchandise	4,149,981,524	(179,006,327)	7,777,021,040	(1,923,956,619)	
Tools and equipment	1,470,071,105	-	1,678,354,169	-	
TOTAL	397,619,665,024	(31,510,030,261)	532,336,906,627	(26,955,944,409)	

Detail of movements of provision for obsolete inventories:

	VND	
	Current year	Previous year
Beginning balance	(26,955,944,409)	(10,510,115,148)
Add: Provision made during the year	(10,097,046,128)	(20,564,518,416)
Less: Revert provision during the year	5,542,960,276	4,118,689,155
Ending balance	(31,510,030,261)	(26,955,944,409)

10. PREPAID EXPENSES

	VND	
	Ending balance	Beginning balance
Short term	8,972,511,923	8,653,554,344
Tools and supplies	3,175,150,107	2,538,609,158
Maintenance and repair	3,050,224,733	4,016,797,362
Rental	401,900,000	240,000,000
Others	2,345,237,083	1,858,147,824
Long term	42,059,071,473	39,382,942,604
Land rental (*)	29,374,180,800	30,248,346,672
Maintenance and repair	7,681,864,023	5,034,904,647
Tools and suppliers	2,758,811,094	3,222,178,615
Others	2,244,215,556	877,512,670
TOTAL	51,031,583,396	48,036,496,948

(*) The prepaid land rental presented the unamortized balance of advance payments made in accordance with lease contracts signed with Sai Gon – Nhon Hoi Industrial Park Joint Stock Company and will expire on 17 June 2066 and 31 July 2069.

11. TANGIBLE FIXED ASSETS

	VND				
	<i>Buildings and structure</i>	<i>Machinery and equipment</i>	<i>Means of transportation</i>	<i>Office equipment</i>	<i>Total</i>
Cost:					
Beginning balance	232,539,286,649	507,610,407,434	51,052,125,034	19,460,030,651	810,661,849,768
Newly purchased	609,279,361	18,023,925,466	1,046,296,296	3,906,936,552	23,586,437,675
Construction in progress completed	1,533,316,342	19,119,237,135	-	-	20,652,553,477
Disposal	(175,880,909)	(4,846,363,381)	-	(222,174,546)	(5,244,418,836)
Ending balance	234,506,001,443	539,907,206,654	52,098,421,330	23,144,792,657	849,656,422,084
<i>In which:</i>	116,451,677,119	264,282,357,907	34,840,772,444	16,306,411,633	431,881,219,103
<i>Fully depreciated</i>					
Accumulated depreciation:					
Beginning balance	138,824,082,950	334,276,711,399	39,948,689,928	16,886,620,047	529,936,104,324
Depreciation for the year	15,674,812,552	33,773,406,419	2,169,185,673	1,360,044,708	52,977,449,352
Disposal	(175,880,909)	(4,846,363,381)	-	(222,174,546)	(5,244,418,836)
Ending balance	154,323,014,593	363,203,754,437	42,117,875,601	18,024,490,209	577,669,134,840
Net carrying amount:					
Beginning balance	93,715,203,699	173,333,696,035	11,103,435,106	2,573,410,604	280,725,745,444
Ending balance	80,182,986,850	176,703,452,217	9,980,545,729	5,120,302,448	271,987,287,244
<i>In which:</i>	53,244,561,754	102,934,979,155	460,246,202	3,728,681,157	160,368,468,268
<i>Pledged as loan security (Note 19)</i>					

12. INTANGIBLE FIXED ASSETS

Cost			VND
	Land use rights (*)	Computer software	Total
Beginning balance	56,767,881,650	19,343,111,742	76,110,993,392
Newly purchased	-	1,524,113,000	1,524,113,000
Construction in progress completed	25,575,711,296	-	25,575,711,296
Ending balance	82,343,592,946	20,867,224,742	103,210,817,688
<i>In which:</i>			
Fully amortized	-	14,092,811,300	14,092,811,300
Accumulated amortization:			
Beginning balance	2,930,983,237	16,356,076,415	19,287,059,652
Amortization for the year	228,189,055	1,456,452,006	1,684,641,061
Ending balance	3,159,172,292	17,812,528,421	20,971,700,713
Net carrying amount:			
Beginning balance	53,836,898,413	2,987,035,327	56,823,933,740
Ending balance	79,184,420,654	3,054,696,321	82,239,116,975

(*) Land use rights represent land use rights of branch offices.

13. CONSTRUCTIONS IN PROGRESS

	VND	
	Ending balance	Beginning balance
Hi-tech pharmaceutical factory	503,589,550,775	158,721,743,664
Powder injection line	23,496,972,309	28,689,372,308
Project of medicinal plants	1,034,280,829	675,840,234
Ho Chi Minh Branch Office Project	-	24,924,000,000
Others	12,041,798,208	20,448,507,415
TOTAL	540,162,602,121	233,459,463,621

14. LONG-TERM INVESTMENTS

	VND	
	Ending balance	Beginning balance
Investment in an associate (Note 14.1)	162,451,534,940	162,728,191,614
Investments in other entities (Note 14.2)	3,513,534,971	3,513,534,971
TOTAL	165,965,069,911	166,241,726,585
Provision for long-term investments	(2,000,000,000)	(2,000,000,000)
NET	163,965,069,911	164,241,726,585

14. LONG-TERM INVESTMENTS (continued)

14.1 Investment in an associate

Name	Business	Beginning and ending balances	
		% of interest and voting right	Cost of investment (VND)
Bidiphar Rubber Joint Stock Company	Manufacture of rubber	33,58%	92.868.048.000

Fair value of this investment is not determined as at 31 December 2025 due to unavailability of market information. However, based on the financial position of this company, the Management believed that the fair value of this investment was higher than its book value.

The investments amount in an associate is as follows:

	VND
	Amount
Cost of investment:	
Beginning and ending balances	92,868,048,000
Accumulated share in post-acquisition profit of the associate:	
Beginning balance	69,860,143,614
Share profit during the year	12,280,174,884
Bonus and welfare fund appropriation	(2,279,579,965)
Dividend received	(14,290,778,000)
Impact of foreign exchange	4,013,526,407
Ending balance	69,583,486,940
Carrying amount:	
Beginning balance	162,728,191,614
Ending balance	162,451,534,940

14. LONG-TERM INVESTMENTS *(continued)*

14.2 Investments in other entities

Name	Business	Status	Beginning and ending balances	
			% of interest	Cost of investment (VND)
Thien Phuc Joint Stock Company	Provide equipment, anti-lightning system	Operating	10,00	2,000,000,000
Nghe An Pharmaceutical Medical Material and Equipment JSC	Pharmaceutical manufacturing	Operating	3,40	1,513,534,971
TOTAL				3,513,534,971
Provision for investments in other entities				(2,000,000,000)
NET				1,513,534,971

Fair value of these investments are not determined as at 31 December 2025 due to unavailability of market information. However, based on the current operation position of these companies, the Management believed that the fair value of those investments was higher than their book value.

15. SHORT-TERM TRADE PAYABLES AND ADVANCES FROM CUSTOMERS

15.1 Short-term trade payables

	VND	
	Ending balance	Beginning balance
Tofflon Science	33,458,881,599	3,020,202,000
Bach Khoa Mechanical and Refrigeration Engineering Co., Ltd.	19,264,779,810	-
Truking Technology Limited	13,001,682,260	3,113,579,550
Trung Son Technology Co., Ltd	1,195,608,000	459,428,000
Aristopharma Ltd	-	13,793,220,000
Minh Hung M&C Joint Stock Company	-	8,718,730,960
Others	150,903,077,579	131,697,739,571
TOTAL	217,824,029,248	160,802,900,081

15.2 Short-term advances from customers

	VND	
	Ending balance	Beginning balance
VP-Pharma Pharmaceutical JSC	5,940,546,470	1,396,512,100
T&T Equipment Joint Stock Company	2,425,500,000	-
Sundial Pharma Joint Stock Company	1,457,124,271	3,444,824,049
Rexton JSC	1,381,288,200	1,626,195,000
HQ Pharmaceutical Limited Liability Company	-	4,945,269,650
Others	4,250,184,545	4,563,951,542
TOTAL	15,454,643,486	15,976,752,341

16. TAX

	VND			
	Beginning balance	Increase during the year	Decrease during the year	Ending balance
Corporate income tax	19,564,487,839	56,610,180,760	(24,728,641,081)	51,446,027,518
Value-added tax ("VAT")	976,543,064	18,632,635,503	(19,203,532,224)	405,646,343
VAT imported goods	(1,350,975,545)	31,871,603,227	(30,817,762,197)	(297,134,515)
Personal income tax ("PIT")	2,952,306,911	27,018,339,075	(28,797,487,293)	1,173,158,693
PIT receivables	(3,296,478)	(45,074,279)	-	(48,370,757)
Import tax	-	467,677,048	(467,677,048)	-
Others	3,725,552,771	7,067,844,255	(10,303,406,131)	489,990,895
TOTAL	25,864,618,562	141,623,205,589	(114,318,505,974)	53,169,318,177
In which:				
Receivable	1,507,912,479			358,416,341
Payable	27,372,531,041			53,527,734,518

17. SHORT-TERM ACCRUED EXPENSES

	VND	
	Ending balance	Beginning balance
Selling expenses	24,773,459,652	19,371,213,021
Others	1,414,590,033	452,344,852
TOTAL	26,188,049,685	19,823,557,873

18. OTHER SHORT-TERM PAYABLES

	VND	
	Ending balance	Beginning balance
Remuneration for Board of Directors ("BOD"), and audit committee	6,407,417,951	6,498,614,659
Dividend	1,600,459,750	121,478,825
Thien Phuc Charity Foundation	1,028,022,166	1,750,718,610
Others	845,357,854	310,274,560
TOTAL	9,881,257,721	8,681,086,654

19. LOANS

	<i>Beginning balance</i>	<i>Drawdown</i>	<i>Repayment</i>	<i>Reclassification</i>	<i>VND</i> <i>Ending balance</i>
Short-term loan	35,913,500,637	139,894,808,772	(148,593,533,781)	16,000,000,000	43,214,775,628
Loan from a bank (Note 19.1)	19,913,500,637	139,894,808,772	(132,593,533,781)		27,214,775,628
Current portion of long-term loan (Note 19.2)	16,000,000,000	-	(16,000,000,000)	16,000,000,000	16,000,000,000
Long-term loans	28,000,000,000	120,000,000,000	-	(16,000,000,000)	132,000,000,000
Loan from a related party (Note 19.2)	28,000,000,000	120,000,000,000	-	(16,000,000,000)	132,000,000,000
TOTAL	63,913,500,637	259,894,808,772	(148,593,533,781)	-	175,214,775,628

19.1 Short-term loans from a bank

<i>Banks</i>	<i>Ending balance (VND)</i>	<i>Maturity date</i>	<i>Interest rate</i> <i>% p.a.</i>	<i>Purpose</i>	<i>Description of collateral</i>
Joint Stock Commercial Bank for Investment and Development of Vietnam – Binh Dinh Branch	14,268,551,500	13 February 2026	4,7	Finance working capital requirements	Unsecured
Joint Stock Commercial Bank for Foreign Trade of Vietnam – Quy Nhon Branch	12,946,224,128	8 March 2026	6,6	Finance working capital requirements	Unsecured
	27,214,775,628				

19.2 Long-term loan

<i>Lender</i>	<i>Ending balance (VND)</i>	<i>Maturity date</i>	<i>Interest rate</i> <i>% p.a.</i>	<i>Purpose</i>	<i>Description of collateral</i>
Gia Lai Development Investment Fund (formerly known as Binh Dinh Development Investment Fund) (Note 30)	148,000,000,000	From 31 March 2026 to 20 August 2032	5,5 - 7,0	Finance its pharmaceutical factory at Nhon Hoi Industrial Park	All future assets of the Bidiphar High-Tech Pharmaceutical Factory Project: Cancer Treatment Medicine Factory (Note 11)
<i>In which:</i>					
<i>Current portion</i>	16,000,000,000				
<i>Non-current portion</i>	132,000,000,000				

20. BONUS AND WELFARE FUND

				VND
	<i>Bonus fund</i>	<i>Welfare fund</i>	<i>Bonus fund for management</i>	<i>Total</i>
Beginning balance	35,444,876,372	61,744,636,563	16,057,321,010	113,246,833,945
Profit after tax appropriation (Note 22.1)	14,597,008,230	14,597,008,230	5,838,803,292	35,032,819,752
Other increase	14,040,000	6,600,000	-	20,640,000
Reclassification	158,700,000	(158,700,000)	-	-
Utilisation	(1,196,700,000)	(2,959,135,256)	(16,033,200,000)	(20,189,035,256)
Ending balance	49,017,924,602	73,230,409,537	5,862,924,302	128,111,258,441

21. SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT FUND

			VND
	<i>Scientific and technological development fund</i>	<i>Scientific and technological development fund formed fixed assets</i>	<i>Total</i>
Beginning balance	88,177,085,243	19,466,934,377	107,644,019,620
Fund appropriation (Note 26)	50,000,000,000	-	50,000,000,000
Depreciation charged to the fund	-	(2,794,666,258)	(2,794,666,258)
Other (decrease) increase	(22,228,023,286)	149,000,000	(22,079,023,286)
Ending balance	115,949,061,957	16,821,268,119	132,770,330,076

22. OWNERS' EQUITY

22.1 Movements in owners' equity

	VND						
	<i>Share capital</i>	<i>Share premium</i>	<i>Treasury shares</i>	<i>Foreign exchange differences</i>	<i>Investment and development fund</i>	<i>Undistributed earnings</i>	<i>Total</i>
Previous year							
Beginning balance	748,835,590,000	20,921,442,000	(1,952,796,558)	8,195,890,640	174,168,770,079	478,393,492,175	1,428,562,388,336
Net profit for the year	-	-	-	-	-	275,181,949,187	275,181,949,187
Appropriation to investment and development fund	-	-	-	-	27,518,194,919	(27,518,194,919)	-
Appropriation to bonus and welfare fund	-	-	-	-	-	(33,021,833,902)	(33,021,833,902)
Stock dividends	187,102,880,000	-	-	-	-	(187,102,880,000)	-
Board of Directors' remuneration	-	-	-	-	-	(5,503,638,984)	(5,503,638,984)
Others	-	-	-	(3,405,339,537)	-	(3,080,543,488)	(6,485,883,025)
Ending balance	935,938,470,000	20,921,442,000	(1,952,796,558)	4,790,551,103	201,686,964,998	497,348,350,069	1,658,732,981,612
Current year							
Beginning balance	935,938,470,000	20,921,442,000	(1,952,796,558)	4,790,551,103	201,686,964,998	497,348,350,069	1,658,732,981,612
Net profit for the year	-	-	-	-	-	291,940,164,606	291,940,164,606
Employee Stock Ownership Plan (Note 22.2)	9,355,000,000	-	-	-	-	-	9,355,000,000
Appropriation to investment and development fund	-	-	-	-	29,194,016,460	(29,194,016,460)	-
Appropriation to bonus and welfare fund (Note 22.5)	-	-	-	-	-	(35,079,018,432)	(35,079,018,432)
Dividends	-	-	-	-	-	(187,107,524,000)	(187,107,524,000)
Board of Directors' remuneration (Note 22.5)	-	-	-	-	-	(5,838,803,292)	(5,838,803,292)
Others (Note 14.1)	-	-	-	4,013,526,407	-	(2,279,579,965)	1,733,946,442
Ending balance	945,293,470,000	20,921,442,000	(1,952,796,558)	8,804,077,510	230,880,981,458	529,789,572,526	1,733,736,746,936

22. OWNERS' EQUITY (continued)

22.2 Capital transactions with owners and distribution of dividends, profits

	VND	
	Current year	Previous year
Contributed share capital		
Beginning balance	935,938,470,000	748,835,590,000
Employee Stock Ownership Plan (i)	9,355,000,000	-
Stock dividends	-	187,102,880,000
Ending balance	<u>945,293,470,000</u>	<u>935,938,470,000</u>
Dividends		
Dividends declared (ii)	187,107,524,000	187,102,880,000
Dividends by shares	-	187,102,880,000
Dividends paid in cash (ii)	185,628,543,075	9,933,200

(i) On 27 August 2025, the Company announced the completion of the issuance of 935,500 shares at an issue price of VND 10,000 per share to its employees under the employee stock option program. This share issuance has been approved by shareholders pursuant to Resolution No. 749/NQ-ĐHĐCĐ dated 27 April 2024 of the 2024 Annual General Meeting of Shareholders, Resolution No. 56/NQ-ĐHĐCĐ 2025 dated 26 April 2025, and Board of Directors Decisions No. 85/QĐ-HĐQT dated 4 June 2025, No. 86/QĐ-HĐQT dated 4 June 2025, No. 87/QĐ-HĐQT dated 4 June 2025, and No. 96/QĐ-HĐQT dated 27 June 2025. Accordingly, the Company's share capital increased from VND 935,938,470,000 to VND 945,293,470,000. According to Official Letter No. 4861/UBCK-QLCB dated 29 August 2025, the State Securities Commission ("SSC") announced that it had received the Company's report on the issuance of 935,500 shares to its employees under the aforementioned employee stock option program. The Company received the 14th amended Business Registration Certificate dated 11 September 2025, approved by the Department of Enterprises and Collective Economy under the Gia Lai Provincial Department of Finance, regarding the updated capital.

(ii) In accordance with the Resolution No. 56/NQ-ĐHĐCĐ 2025 dated 26 April 2025, the General Meeting of Shareholders approved the plan for the dividend of 2024 with each share receiving 20% of par value of share.

22.3 Share capital

	Number of shares	
	Ending balance	Beginning balance
Authorized shares	94,529,347	93,593,847
Shares issued and fully paid		
<i>Ordinary shares</i>	94,529,347	93,593,847
Re-purchase treasury shares		
<i>Ordinary shares</i>	(40,085)	(40,085)
Shares in circulation		
<i>Ordinary shares</i>	94,489,262	93,553,762

Each ordinary share with par value of VND 10,000. The holders of the ordinary shares are entitled to receive dividends as and when declared by the Company. Each ordinary share carries one vote per share without restriction.

22. OWNERS' EQUITY (continued)

22.4 Contributed share capital

	Ending balance		Beginning balance	
	Amount VND	Ownership %	Amount VND	Ownership %
Binh Dinh Development Investment Fund	124,856,060,000	13.21	124,856,060,000	13.34
KWE Beteiligungen AG	100,535,500,000	10.64	93,685,500,000	10.01
Others	719,501,060,000	76.11	716,996,060,000	76.61
Treasury shares	400,850,000	0.04	400,850,000	0.04
TOTAL	<u>945,293,470,000</u>	<u>100.00</u>	<u>935,938,470,000</u>	<u>100.00</u>

22.5 Earnings per share

Basic and diluted earnings per share are calculated as follows:

	VND	
	Current year	Previous year
Net profit after tax	291,940,164,606	275,181,949,187
Less:		
• Bonus and welfare fund (*)	(35,079,018,432)	(33,021,833,902)
• Board of Directors' remuneration (*)	(5,838,803,292)	(5,503,638,984)
Net profit attributable to ordinary equity holders of the parent company	<u>251,022,342,882</u>	<u>236,656,476,301</u>
Weighted average number of ordinary shares	93,876,702	93,553,762
Basic earnings per share (VND/share)	<u>2,674</u>	<u>2,530</u>
Diluted earnings per share (VND/share)	<u>2,674</u>	<u>2,530</u>

(*) Net profit used to compute earnings per share for the year ended 31 December 2025 was adjusted for the provisional allocation to bonus and welfare fund at 12% and Board of Directors' remuneration at 2% of 2025 profit after tax following the Shareholders Meeting's Resolution No 26/NQ-ĐHĐCĐ dated 26 April 2025.

There have been no dilutive potential ordinary shares during the year and up to the date of these consolidated financial statements.

23. OTHER FUNDS

Other funds represent funds allocated by the Department of Science and Technology of Binh Dinh Province (“TECHBID”) in relation to the contract of “Research and development and apply technology to produce some drugs used cancer treatment at Binh Dinh Pharmaceutical and Medical Equipment”, “Researching and developing of dosage forms and assessment of the effects of remedies for treating injuries in traditional martial arts of Binh Dinh”; and contracts for researching, developing and applying of propagation, planting and processing of a number of medicinal plants.

24. REVENUES

24.1 Revenues from sale of goods and rendering of services

	VND	
	Current year	Previous year
Gross revenues	1,946,612,659,958	1,817,259,164,083
<i>Of which:</i>		
Sales of pharmaceutical finished goods	1,879,187,145,157	1,752,251,384,321
Sales of pharmaceutical merchandises	39,826,575,402	35,696,823,885
Sales of materials, packaging, tools and supplies	13,348,581,085	18,586,867,418
Sales of medical supplies	4,779,241,533	8,381,818,232
Others	9,471,116,781	2,342,270,227
Less	(81,233,070,327)	(89,710,776,512)
Trade discounts and sales allowances	(74,727,922,982)	(86,135,200,447)
Sales returns	(6,505,147,345)	(3,575,576,065)
NET	1,865,379,589,631	1,727,548,387,571

24.2 Finance income

	VND	
	Current year	Previous year
Interest income	20,035,844,420	11,399,296,546
Dividend earned	-	205,710,000
Foreign exchange gains	5,153,319,762	1,754,141,812
TOTAL	25,189,164,182	13,359,148,358

25. COSTS OF GOODS SOLD AND SERVICES RENDERED

	VND	
	Current year	Previous year
Cost of pharmaceutical finished goods sold	913,524,858,580	818,509,961,544
Cost of pharmaceutical merchandises sold	38,026,742,404	34,057,609,049
Cost of materials, packaging, tools and supplies sold	18,819,258,291	33,123,410,276
Cost of medical supplies sold	3,372,062,008	8,149,559,493
Others	7,257,873,982	1,134,598,354
TOTAL	981,000,795,265	894,975,138,716

26. SELLING EXPENSES AND GENERAL AND ADMINISTRATIVE EXPENSES

	VND	
	Current year	Previous year
Selling expenses	418,308,462,079	404,195,096,035
Labor cost	193,488,387,126	199,626,047,458
External services expenses	55,616,037,417	59,112,834,846
Depreciation	3,088,266,715	3,213,450,544
Others	166,115,770,821	142,242,763,187
General and administrative expenses	139,794,488,425	122,785,668,843
Scientific and technological development expense (Note 21)	50,000,000,000	23,000,000,000
Labor cost	48,957,811,306	47,180,257,016
External services expenses	17,143,169,758	12,088,764,524
Depreciation	8,782,404,230	9,952,145,490
Reversal of provision	(4,817,948,655)	(330,125,014)
Others	19,729,051,786	30,894,626,827
TOTAL	558,102,950,504	526,980,764,878

27. FINANCE EXPENSES

	VND	
	Current year	Previous year
Payment discount	8,261,754,499	8,168,738,992
Interest expenses	3,846,557,387	4,058,137,920
Foreign exchange loss	2,508,913,003	2,701,633,484
Provision for diminution in value of investment	-	2,000,000,000
TOTAL	14,617,224,889	16,928,510,396

28. PRODUCTION AND OPERATING COSTS

	VND	
	Current year	Previous year
Raw materials and merchandise	626,361,730,399	669,140,873,557
Labor costs	342,578,095,607	337,380,955,381
External services expenses	146,603,455,366	145,543,018,230
Depreciation and amortization	51,021,340,822	48,112,079,145
(Reversal) provision	(263,862,803)	16,115,704,247
Other expenses	239,193,345,090	198,989,623,120
TOTAL	1,405,494,104,481	1,415,282,253,680

29. CORPORATE INCOME TAX

The Group has the obligation to pay corporate income tax ("CIT") at the rate of:

- Normal CIT rate 20% of taxable profits earned from manufacturing activities of Nguyen Thai Hoc Factory; and
- An exemption from CIT for four (4) years commencing from the first year in which a taxable profit is earned (2023), and a 50% reduction of the applicable CIT tax rate for the following nine (9) years of taxable profits earned from manufacturing activities of Nhon Hoi Factory.

The Group's subsidiaries has the obligations to pay CIT at the rates of 20% of taxable profits.

The Group's tax returns are subject to examination by the tax authorities. As the application of tax laws and regulations are susceptible to varying interpretations, the amounts reported in the consolidated financial statements could be changed at a later date upon final determination by the tax authorities.

29.1 CIT expenses

	VND	
	Current year	Previous year
Current CIT expense	56,582,178,164	54,074,436,040
Adjustment for under accrual of tax from prior years	28,002,596	1,202,071,012
Deferred tax income	56,610,180,760	55,276,507,052
	(2,468,308,986)	(5,322,931,908)
TOTAL	54,141,871,774	49,953,575,144

The reconciliation between CIT expense and the accounting profit multiplied by CIT rate is presented below:

	VND	
	Current year	Previous year
Accounting profit before tax	346.082.036.380	325.135.524.331
At CIT rate applicable	69,216,407,276	65,027,104,866
<i>Adjustments:</i>		
Exempted income	(13,747,723,205)	(12,755,358,591)
Non-deductible expenses	1,117,119,264	2,154,351,022
Share profit from the associate	(2,456,034,977)	(5,412,617,986)
Adjustment for under accrual of tax from prior years	28,002,596	1,202,071,012
Others	(15,899,180)	(261,975,179)
CIT expenses	54,141,871,774	49,953,575,144

29.2 Current CIT expense

The current CIT payable is based on taxable profit for the year. The taxable profit of the Group for the year differs from the profit as reported in the consolidated income statement because it excludes items of income or expenses that are taxable or deductible in other year and it further excludes items that are not taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted at the balance sheet date.

29. CORPORATE INCOME TAX (continued)

29.3 Deferred income tax

The following are the deferred tax assets recognized by the Group, and the movements thereon, during the current and previous years:

	Consolidated balance sheet		Consolidated income statement	
	Ending balance	Beginning balance	Current year	Previous year
Depreciation	7,394,572,128	5,872,120,082	1,522,452,046	1,528,802,863
Provision for obsolete inventories	6,302,006,052	5,391,188,882	910,817,170	3,289,165,853
Provision for severance allowance	1,558,112,458	1,453,416,745	104,695,713	122,972,725
Provision for diminution in value of investment	400,000,000	400,000,000	-	400,000,000
Unrealize profit	105,721,293	175,377,236	(69,655,943)	(18,009,533)
Deferred tax assets	15,760,411,931	13,292,102,945		
Net deferred tax income			2,468,308,986	5,322,931,908

30. TRANSACTIONS WITH RELATED PARTIES

List of related parties that have a controlling relationship with the Company and related parties that have transactions with the Company during the year and as at 31 December 2025 is as follows:

Related parties	Relationship
Gia Lai Development Investment Fund (formerly known as Binh Dinh Development Investment Fund)	Major shareholder
KWE Beteiligungen AG	Major shareholder
Bidiphar Rubber Joint Stock Company	Associate

Significant transactions with related parties during the current year and previous year were as follows:

Related party	Transactions	VND	
		Current year	Previous year
Gia Lai Development Investment Fund	Loan	120,000,000,000	-
	Repayment of loan	16,000,000,000	16,000,000,000
	Interest expense	3,831,229,000	3,811,068,000
	Interest expense payable	240,688,000	-
	Dividend paid	18,737,100,000	24,971,210,000
Bidiphar Rubber Joint Stock Company	Dividend received	14,290,778,000	17,863,472,500

Amounts due from related parties at the balance sheet date were as follows:

Related party	Transactions	VND	
		Ending balance	Beginning balance
Loan			
Gia Lai Development Investment Fund	Loan	148,000,000,000	44,000,000,000

30. TRANSACTIONS with related PARTIES (continued)

Remuneration for the members of the Board of Directors (“BOD”), the management and the internal audit committee under BOD are as follows:

<i>Individuals</i>	<i>Title</i>	<i>Current year</i>	<i>Previous year</i>
Mrs Pham Thi Thanh Huong	General Director/ Member of BOD	8,334,958,642	3,872,050,000
Mr Nguyen Ngoc Dung	Deputy General Director/ Member of BOD	5,038,977,580	3,146,191,596
Mrs Banh Thi Ngoc Quynh	Deputy General Director	3,441,175,397	2,270,030,000
Mr Huynh Ngoc Oanh	Deputy General Director (to 1 January 2025)	1,665,500,000	2,842,700,000
Mr Truong Thanh Liem	Member of BOD	1,144,406,667	1,383,165,000
Mr Ta Nam Binh	Chairman/Independent member of BOD	968,000,000	650,000,000
Mrs Nguyen Thi Minh Giang	Independent member of BOD/Chairwoman of the Audit Committee	817,000,000	-
Mr Nguyen Tien Hai	Member of BOD	667,000,000	750,000,000
Mr Phan Tan Thu	Member of BOD/ Member of Internal Audit	767,000,000	30,000,000
Mr Hoang Van Thang	Independent member of BOD/Member of Internal Audit (to 27 April 2024)	-	580,000,000
Mr Dau Minh Lam	Member of BOD (to 27 April 2024)	-	550,000,000
TOTAL		22,844,018,286	16,074,136,596

31. OFF BALANCE SHEET ITEMS

Foreign currencies:

	<i>Ending balance</i>	<i>Beginning balance</i>
<i>United States dollar (USD)</i>	60,745.43	2,596.70
<i>Euro (EUR)</i>	128.61	145.82

32. OPERATING LEASE AND CAPITAL COMMITMENTS

Operating lease commitments

The Group leases its warehouse and office under operating lease arrangements. The minimum lease commitments at the balance sheet date under the operating lease agreements were as follows:

	<i>VND</i>	
	<i>Ending balance</i>	<i>Beginning balance</i>
Less than 1 year	659,330,000	1,633,874,832
From 1 year to 5 years	366,000,000	822,000,000
TOTAL	1,025,330,000	2,455,874,832

Capital commitments

As at 31 December 2025, the Group has contractual commitment for the construction of pharmaceutical factory as follows:

	<i>VND</i>		
<i>Related parties</i>	<i>Contracted amount</i>	<i>Recognized amount</i>	<i>Remaining commitment</i>
Bidiphar High-tech pharmaceutical factory	714,222,612,487	503,589,550,775	210,633,061,712
Penicillin line project	24,091,972,569	23,496,972,309	595,000,260
TOTAL	738,314,585,056	527,086,523,084	211,228,061,972

33. CONTINGENT LIABILITIES

According to the Environmental Protection Law 2020 and Decree No. 08/2022/ND-CP dated 10 January 2022 of the Government detailing the implementation of certain articles of the Environmental Protection Law, manufacturers and importers of certain types of products and packaging will be responsible for recycling those products and packaging according to the mandatory recycling rates as specified in the roadmap, starting from 1 January 2024.

The Group currently engages in the production of commercial packaging for pharmaceutical goods in accordance with the Laws on pharmaceuticals. Accordingly, the Group is identified as being subject to the responsibility of recycling and handling the packaging of its products, and is required to make financial contributions to the Vietnam Environmental Protection Fund according to the mandatory recycling rates and specifications stipulated in Chapter VI, Section 1, Articles 77 to 82 of Decree No. 08/2022/ND-CP.

As of the date of this consolidated financial statement, the Management is in the process of estimating the potential recycling obligations for packaging that may arise. According to the Management's assessment, the potential recycling obligation for packaging is not material to the consolidated financial statements.

34. EVENTS AFTER THE BALANCE SHEET DATE

There is no matter or circumstance that has arisen since the consolidated balance sheet date that requires adjustment or disclosure in the consolidated financial statements of the Group.

Gia Lai Province, Vietnam
20 March 2026



Le Thi Kieu My
Preparer



Do Huy Phuong
Chief Accountant



Pham Thi Thanh Huong
General Director



 <https://bidiphar.com>

 info@bidiphar.com

 +84 (256) 3846500

 No.498 Nguyen Thai Hoc Street,
Quy Nhon Nam Ward, Gia Lai